Publications: Prof Graham Foster

La Mura V, Colombo M, Foster GR, Angeli P, Miesbach W, Klamroth R, Pierce GF, O'Mahony B et al. ( 2024 ) . The management of liver disease in people with congenital bleeding disorders: guidance from EAHAD, EHC, ISTH, WFH . Journal of Thrombosis and Haemostasis

Etoori D, Simmons R, Desai M, Foster GR, Stuart A, Sabin C, Mandal S, Rosenberg W ( 2024 ) . Results from a retrospective case finding and re-engagement exercise for people previously diagnosed with hepatitis C virus to increase uptake of directly acting antiviral treatment . BMC Public Health vol. 24 , ( 1 )

Alamneh TS, Walker JG, Lim AG, Alam E, Hamid S, Foster GR, Choudhry N, Ansari MA et al. ( 2024 ) . Changes in the prevalence of hepatitis B and C viral infections in Sindh province, Pakistan: Findings from two sero‐surveys in 2007 and 2019 . Journal of Viral Hepatitis vol. 31 , ( 11 ) 645 - 656 .

Samartsidis P, Harris RJ, Dillon J, Desai M, Foster GR, Gunson R, Ijaz S, Mandal S et al. ( 2024 ) . Evaluating the effect of direct-acting antiviral agent treatment scale-up on Hepatitis C virus prevalence among people who inject drugs in UK . International Journal of Drug Policy

Farooq HZ, James M, Abbott J, Oyibo P, Divall P, Choudhry N, Foster GR ( 2024 ) . Risk factors for hepatocellular carcinoma associated with hepatitis C genotype 3 infection: A systematic review . World Journal of Gastrointestinal Oncology vol. 16 , ( 4 ) 1596 - 1612 .

Maina A, Foster GR ( 2024 ) . Hepatitis after gene therapy, what are the possible causes? . Journal of Viral Hepatitis vol. 31 , ( S1 ) 14 - 20 .

Tuddenham EGD, Foster GR ( 2024 ) . The complex, confusing and poorly understood immune responses to AAV‐mediated gene transfer in haemophilia—Is more or less immunosuppression required? . Journal of Viral Hepatitis vol. 31 , ( S1 ) 21 - 25 .

Marshall AD, Willing AR, Kairouz A, Cunningham EB, Wheeler A, O’Brien N, Perera V, Ward JW et al. ( 2024 ) . Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions . The Lancet Gastroenterology & Hepatology vol. 9 , ( 4 ) 366 - 382 .

Arif A, Hasnain A, Chaudhry A, Asim M, Shafqat MN, Altaf A, Saba N, Kemos P et al. ( 2023 ) . HepFREEPak: protocol for a multi-centre, prospective observational study examining efficacy and impact of current therapies for the treatment of hepatitis C in Pakistan and reporting resistance to antiviral drugs: study protocol . BMC Public Health vol. 23 , ( 1 )

Razavi-Shearer D, Child H, Razavi-Shearer K, Voeller A, Razavi H, Buti M, Tacke F, Terrault N et al. ( 2023 ) . Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories . Journal of Hepatology vol. 80 , ( 2 ) 232 - 242 .

Mücke MM, Fong S, Foster GR, Lillicrap D, Miesbach W, Zeuzem S ( 2023 ) . Adeno-associated viruses for gene therapy – clinical implications and liver-related complications, a guide for hepatologists . Journal of Hepatology vol. 80 , ( 2 ) 352 - 361 .

Alter HJ, Barnes E, Biondi MJ, Cox AL, Eberts JD, Feld JJ, Liang TJ, Morrison J et al. ( 2023 ) . Joint statement in support of hepatitis C human challenge studies . The Lancet Gastroenterology & Hepatology vol. 8 , ( 11 ) 967 - 969 .

Schmidt M, Foster GR, Coppens M, Thomsen H, Dolmetsch R, Heijink L, Monahan PE, Pipe SW ( 2023 ) . Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B . Blood Advances vol. 7 , ( 17 ) 4966 - 4969 .

Miesbach W, Foster GR, Peyvandi F ( 2023 ) . “Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologists”: reply . Journal of Thrombosis and Haemostasis vol. 21 , ( 8 ) 2307 - 2308 .

Miesbach W, Foster GR, Peyvandi F ( 2023 ) . "Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologists": reply . Journal of Thrombosis and Haemostasis vol. 21 , ( 7 ) 2000 - 2001 .

Niyomsri S, Walker J, Alam E, Arif A, Asim M, Ather B, Azam M, Chaudhry A et al. ( 2023 ) . FRI-172 The impact of hepatitis C and socio-demographic variables on Health-related quality of life among patients in Pakistan . Journal of Hepatology vol. 78 ,

Razavi HA, Buti M, Terrault NA, Zeuzem S, Yurdaydin C, Tanaka J, Aghemo A, Akarca US et al. ( 2023 ) . Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries . Journal of Hepatology vol. 79 , ( 2 ) 576 - 580 .

Jacobson IM, Bourgeois S, Mathurin P, Thuluvath P, Ryder SD, Gerken G, Hernandez C, Vanstraelen K et al. ( 2023 ) . The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis . Journal of Viral Hepatitis vol. 30 , ( 5 ) 448 - 454 .

Ward Z, Fraser H, Trickey A, Kesten J, Gibson A, Reid L, Gordon F, Miners A et al. ( 2023 ) . A modelling study of the impact of scaling up of HCV case finding and treatment for people who inject drugs in English region of Bristol and Severn . JOURNAL OF HEPATOLOGY . vol. 78 , S909 - S909 .

Lee W-YJ, Foster GR ( 2023 ) . Hepatitis C . Encyclopedia of Cell Biology , Elsevier

Jugnarain DV, Halford R, Smith S, Hickman M, Samartsidis P, Foster GR ( 2023 ) . Role of peer support in a hepatitis C elimination programme (vol 29, pg 43, 2022) . JOURNAL OF VIRAL HEPATITIS

Miesbach W, Foster GR, Peyvandi F ( 2022 ) . Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologists . Journal of Thrombosis and Haemostasis vol. 21 , ( 2 ) 200 - 203 .

Allison MED, Verne J, Bernal W, Clayton M, Cox S, Dhanda A, Dillon JF, Ferguson J et al. ( 2022 ) . Deaths from alcohol-related liver disease in the UK: an escalating tragedy . The Lancet vol. 401 , ( 10375 ) 418 - 420 .

Miesbach W, Foster GR, Peyvandi F ( 2022 ) . Liver-related aspects of gene therapy for haemophilia: Call to action for collaboration between haematologists and hepatologists . Journal of Hepatology vol. 78 , ( 3 ) 467 - 470 .

Tinelli M, Wittenberg R, Cornes M, Aldridge RW, Clark M, Byng R, Foster G, Fuller J et al. ( 2022 ) . The economic case for hospital discharge services for people experiencing homelessness in England: An in‐depth analysis with different service configurations providing specialist care . Health & Social Care in the Community vol. 30 , ( 6 ) e6194 - e6205 .

Iveson P, Drysdale K, Marks MT, Dufaur L, Cutino-Moguel T, Dakshina S, Foster G, Young E ( 2022 ) . OP37 Achieving over 50% uptake in routine blood-borne virus testing in an east London emergency department . Conference: Abstractsa30 - a31 .

Drysdale K, Cutino-Moguel M-T, Dakshina S, Dhairyawan R, Moloney J, Orkin PC, Sarner L, Ullah S et al. ( 2022 ) . P76 Going, going, gone? Routine emergency department hepatitis C testing can drive elimination efforts. Data from a single UK urban centre show sustained significant decreases in hepatitis C viraemia over time . Conference: Abstractsa89 - a89 .

Kazankov K, Novelli S, Chatterjee DA, Phillips A, Balaji A, Raja M, Foster G, Tripathi D et al. ( 2022 ) . Evaluation of CirrhoCare® – a digital health solution for home management of individuals with cirrhosis . Journal of Hepatology vol. 78 , ( 1 ) 123 - 132 .

Chang WH, Foster GR, Kelly DA, Lai AG ( 2022 ) . Depression, anxiety, substance misuse and self-harm in children and young people with rare chronic liver disease . BJPsych Open vol. 8 , ( 5 )

Buti M, Craxi A, Foster GR, Maticic M, Negro F, Zeuzem S, Zoulim F ( 2022 ) . Viral hepatitis elimination: Towards a hepatitis-free world . Journal of Hepatology vol. 77 , ( 5 ) 1444 - 1447 .

Misak C, Naylor CD, Tonelli M, Greenhalgh T, Foster G ( 2022 ) . Case Report: What—or who—killed Frank Ramsey? Some reflections on cause of death and the nature of medical reasoning . Wellcome Open Research vol. 7 ,

Morgan JR, Marsh E, Savinkina A, Shilton S, Shadaker S, Tsertsvadze T, Kamkamidze G, Alkhazashvili M et al. ( 2022 ) . Determining the lower limit of detection required for HCV viral load assay for test of cure following direct‐acting antiviral‐based treatment regimens: Evidence from a global data set . Journal of Viral Hepatitis vol. 29 , ( 6 ) 474 - 486 .

Dermont M, Sullivan R, Sibal B, Foster G, Mandal S ( 2022 ) . Hepatitis C diagnosis and management: a primary care and public health partnership approach . British Journal of General Practice vol. 72 , ( 715 ) 89 - 92 .

Chang WH, Mueller SH, Chung S-C, Foster GR, Lai AG ( 2022 ) . Increased burden of cardiovascular disease in people with liver disease: unequal geographical variations, risk factors and excess years of life lost . Journal of Translational Medicine vol. 20 , ( 1 )

Flamm SL, Foster GR, Bourliere M, Zeuzem S, Cooper C, Chan HLY, Kottilil S, Sulkowski MS et al. ( 2022 ) . CURING HCV WITH DIRECT-ACTING ANTIVIRAL (DAA) TREATMENT: ADHERENCE AND RAPID ONSET OF HCV RNA UNDETECTABILITY AFTER 4 WEEKS OF TREATMENT WITH SOFOSBUVIR/VELPATASVIR . HEPATOLOGY . vol. 76 , S344 - S345 .

Hiebert L, Nassar I, Nunez V, Kondili L, Mandal S, Foster G, Garcia-Samaniego Rey FJ, Bruggmann P et al. ( 2022 ) . National hepatitis elimination profiles: progress towards HBV and HCV elimination in five European countries . JOURNAL OF HEPATOLOGY . vol. 77 , S238 - S238 .

Kelly D, Lloyd C, Brown M, Ahmed K, Carey I, Tizzard S, Crook J, North-Lewis P et al. ( 2022 ) . Treating children with HCV close to home through a virtual national multidisciplinary network . JOURNAL OF HEPATOLOGY . vol. 77 , S551 - S551 .

Smith DA, Fernandez-Antunez C, Magri A, Bowden R, Chaturvedi N, Fellay J, McLauchlan J, Foster GR et al. ( 2021 ) . Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure . Nature Communications vol. 12 , ( 1 )

Lai AG, Chang WH, Parisinos CA, Katsoulis M, Blackburn RM, Shah AD, Nguyen V, Denaxas S et al. ( 2021 ) . An informatics consult approach for generating clinical evidence for treatment decisions . BMC Medical Informatics and Decision Making vol. 21 , ( 1 )

Jugnarain DV, Halford R, Smith S, Hickman M, Samartsidis P, Foster GR ( 2021 ) . A two‐stage drop‐the‐losers design for time‐to‐event outcome using a historical control arm . Journal of Viral Hepatitis vol. 21 , ( 1 ) 268 - 288 .

Cornes M, Aldridge RW, Biswell E, Byng R, Clark M, Foster G, Fuller J, Hayward A et al. ( 2021 ) . Improving care transfers for homeless patients after hospital discharge: a realist evaluation . Health and Social Care Delivery Research vol. 9 , ( 17 ) 1 - 186 .

Clark M, Cornes M, Whiteford M, Aldridge R, Biswell E, Byng R, Foster G, Fuller JS et al. ( 2021 ) . Homelessness and integrated care: an application of integrated care knowledge to understanding services for wicked issues . Journal of Integrated Care vol. 30 , ( 1 ) 3 - 19 .

Choudhry N, Drysdale K, Usai C, Leighton D, Sonagara V, Buchanan R, Nijjar M, Thomas S et al. ( 2021 ) . Disparities of SARS-CoV-2 Nucleoprotein-Specific IgG in Healthcare Workers in East London, UK . Frontiers in Medicine vol. 8 ,

Williams R, Alessi C, Alexander G, Allison M, Aspinall R, Batterham RL, Bhala N, Day N et al. ( 2021 ) . New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK . The Lancet vol. 397 , ( 10286 ) 1770 - 1780 .

Salmon HA, Briscoe S, Foster GR, Pitt MA ( 2021 ) . Targeted vs opportunistic screening for viral hepatitis among UK migrant communities: a cost-effectiveness analysis . British Journal of Healthcare Management vol. 27 , ( 3 ) 90 - 98 .

Mecci J, Kemos P, Foster G ( 2021 ) . Patients with cirrhosis show an improvement in dynamic liver function following the eradication of hepatitis C virus with direct acting antivirals . JOURNAL OF HEPATOLOGY . vol. 75 , S790 - S791 .

Jugnarain D, Samartsidis P, Halford R, Smith S, Foster G ( 2021 ) . Peer support in a national hepatitis C elimination program-pseudo-randomised analysis of impact in 30, 729 patients . JOURNAL OF HEPATOLOGY . vol. 75 , S292 - S293 .

Jason Lee W-Y, Jones M, Wing PAC, Rajagopal S, Foster GR ( 2020 ) . The A150V polymorphism of genotype 3 hepatitis C virus polymerase inhibits interferon alfa by suppressing protein kinase R activation . Cellular and Molecular Gastroenterology and Hepatology

Lai AG, Pasea L, Banerjee A, Hall G, Denaxas S, Chang WH, Katsoulis M, Williams B et al. ( 2020 ) . Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study . BMJ Open vol. 10 , ( 11 )

Collaborators PO ( 2020 ) . The case for simplifying and using absolute targets for viral hepatitis elimination goals . Journal of Viral Hepatitis vol. 28 , ( 1 ) 12 - 19 .

Johnson PJ, Berhane S, Walker AJ, Gordon FH, Ryder SD, McPherson S, Sreedharan A, Ustianowski AA et al. ( 2020 ) . Impact of direct‐acting antiviral agents on liver function in patients with chronic hepatitis C virus infection . Journal of Viral Hepatitis vol. 28 , ( 1 ) 168 - 176 .

Lee W-YJ, Jones M, Wing PA, Rajagopal S, Foster GR ( 2020 ) . O4 Amino acid substitution in genotype 3a hepatitis C virus polymerase protein affects responses to sofosbuvir and interferon alpha and inhibits apoptosis . Gut vol. 69 , ( Suppl 1 ) a2 - a3 .

Janarthanan S, Drysdale K, Dhaliwal J, Tan A, Foster G, Kallis Y, Sharma V ( 2020 ) . P70 The Covid-19 pandemic hepatology ambulatory unit: a future model for hepatology outpatient services . Gut . Conference: Abstracts vol. 69 , a40 - a41 .

Simmonds P, Cuypers L, Irving WL, McLauchlan J, Cooke GS, Barnes E, Consortium S-H, Ansari MA et al. ( 2020 ) . Impact of virus subtype and host IFNL4 genotype on large-scale RNA structure formation in the genome of hepatitis C virus . RNA vol. 26 , ( 11 )

Sinkala E, Vinikoor M, Siyunda AM, Zyambo K, Besa E, Nsokolo B, Wandeler G, Foster GR et al. ( 2020 ) . Hepatosplenic schistosomiasis in Zambian adults is characterized by increased liver stiffness: A nested case-control study . Heliyon vol. 6 , ( 7 )

Heath H, Britton G, Kudo H, Renney G, Ward M, Hutchins R, Foster GR, Goldin RD et al. ( 2020 ) . Stat2 loss disrupts damage signalling and is protective in acute pancreatitis . The Journal of Pathology vol. 252 , ( 1 ) 41 - 52 .

Drysdale K, Ntuli Y, Bestwick J, Gelson W, Agarwal K, Forton D, Mutimer D, Elsharkawy AM et al. ( 2020 ) . English hepatitis C registry data show high response rates to directly acting anti‐virals, even if treatment is not completed . Alimentary Pharmacology & Therapeutics vol. 52 , ( 1 ) 168 - 181 .

Marcellin P, Xie Q, Paik SW, Flisiak R, Piratvisuth T, Petersen J, Asselah T, Cornberg M et al. ( 2020 ) . Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B . PLOS ONE vol. 15 , ( 4 )

Foster GR, Reddy KR ( 2020 ) . Clinical Dilemmas in Viral Liver Disease, Second Edition .

Agarwal K, Afdhal N, Coffin C, Fung S, Dusheiko G, Foster G, Elkhashab M, Tam E et al. ( 2020 ) . Liver toxicity in the Phase 2 Catalyst 206 trial of Inarigivir 400 mg daily added to a nucleoside in HBV EAg negative patients . JOURNAL OF HEPATOLOGY . vol. 73 , S125 - S125 .

Foster GR, Reddy KR ( 2020 ) . Preface . Clinical Dilemmas in Viral Liver Disease, Second Edition

Drysdale K, Ntuli Y, Bestwick J, Townley C, Mahomed F, Foster G ( 2020 ) . The English hepatitis C registry shows only a modest effect from non-completion of directly-acting antivirals for hepatitis C: SVR rates over 80% in genotype 1, 2 or 3 HCV if more than one third of planned treatment is completed . JOURNAL OF HEPATOLOGY . vol. 73 , S348 - S348 .

Williams R, Aithal G, Alexander GJ, Allison M, Armstrong I, Aspinall R, Baker A, Batterham R et al. ( 2019 ) . Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK . The Lancet vol. 395 , ( 10219 ) 226 - 239 .

Fawsitt CG, Vickerman P, Cooke GS, Consortium SH, Barnes E, Ball J, Brainard D, Burgess G et al. ( 2019 ) . Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus . Value in Health vol. 23 , ( 2 ) 180 - 190 .

Dore GJ, Feld JJ, Thompson A, Martinello M, Muir AJ, Agarwal K, Müllhaupt B, Wedemeyer H et al. ( 2019 ) . Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial . Journal of Hepatology vol. 72 , ( 3 ) 431 - 440 .

Bradshaw D, Mbisa JL, Geretti AM, Healy BJ, Cooke GS, Foster GR, Thomson EC, McLauchlan J et al. ( 2019 ) . Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group . Journal of Infection vol. 79 , ( 6 ) 503 - 512 .

Hickman M, Dillon JF, Elliott L, De Angelis D, Vickerman P, Foster G, Donnan P, Eriksen A et al. ( 2019 ) . Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol) . BMJ Open vol. 9 , ( 9 )

Ansari MA, Aranday-Cortes E, Ip CL, Da Silva Filipe A, Lau SH, Bamford C, Bonsall D, Trebes A et al. ( 2019 ) . Interferon lambda 4 impacts the genetic diversity of hepatitis c virus . eLife vol. 8 ,

Wei L, Pavlovic V, Bansal AT, Chen X, Foster GR, He H, Kao J, Lampertico P et al. ( 2019 ) . Genetic variation in FCER1A predicts peginterferon alfa‐2a‐induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B . Journal of Viral Hepatitis vol. 26 , ( 9 ) 1040 - 1049 .

Forrest EH, Storey N, Sinha R, Atkinson SR, Vergis N, Richardson P, Masson S, Ryder S et al. ( 2019 ) . Baseline neutrophil‐to‐lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis . Alimentary Pharmacology & Therapeutics vol. 50 , ( 4 ) 442 - 453 .

Lawitz E, Gane E, Feld JJ, Buti M, Foster GR, Rabinovitz M, Burnevich E, Katchman H et al. ( 2019 ) . Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6 . Journal of Viral Hepatitis vol. 26 , ( 9 ) 1127 - 1138 .

Bundle N, Balasegaram S, Parry S, Ullah S, Harris RJ, Ahmad K, Foster GR, Tong CYW et al. ( 2019 ) . Seroprevalence and demographic factors associated with hepatitis B, hepatitis C and HIV infection from a hospital emergency department testing programme, London, United Kingdom, 2015 to 2016 . Eurosurveillance vol. 24 , ( 27 )

Shokatpour N, Vaezjalali M, Foster GR, Sali S ( 2019 ) . Nucleotide Substitutions in Hepatitis B Viruses Derived from Chronic HBV Patients . Mediterranean Journal of Hematology and Infectious Diseases vol. 11 , ( 1 ) e2019046 - e2019046 .

Mecci AJ, Kemos P, Leen C, Lawson A, Richardson P, Khakoo SI, Agarwal K, Mutimer D et al. ( 2019 ) . The association between hepatocellular carcinoma and direct‐acting anti‐viral treatment in patients with decompensated cirrhosis . Alimentary Pharmacology & Therapeutics vol. 50 , ( 2 ) 204 - 214 .

Fawsitt CG, Vickerman P, Cooke G, Welton NJ, STOP-HCV Consortium ( 2019 ) . A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus . Value in Health vol. 22 , ( 6 ) 693 - 703 .

Wing PAC, Jones M, Cheung M, DaSilva S, Bamford C, Lee W-YJ, Aranday-Cortes E, Da Silva Filipe A et al. ( 2019 ) . Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir . Gastroenterology vol. 157 , ( 3 ) 692 - 704.e9 .

Mecci J, Maxan M-E, Kemos P, Telfer P, Barroso F, Foster G, Banu K ( 2019 ) . FRI-437-Diagnosis of sickle cell liver disease may be aided by non-invasive tests . Journal of Hepatology . vol. 70 , e586 - e587 .

Stagg HR, Surey J, Francis M, MacLellan J, Foster GR, Charlett A, Abubakar I ( 2019 ) . Improving engagement with healthcare in hepatitis C: a randomised controlled trial of a peer support intervention . BMC Medicine vol. 17 , ( 1 )

Drysdale K, Townley C, Mahomed F, Foster G ( 2019 ) . LBO-07-Effectiveness of therapy in 16,567 directly-acting antiviral treated people in England: high response rates in genotype 3 hepatitis C infection regardless of degree of fibrosis, but ribavirin improves response in cirrhosis . Journal of Hepatology . vol. 70 ,

Naganuma A, Chayama K, Notsumata K, Gane E, Foster GR, Wyles D, Kwo P, Crown E et al. ( 2019 ) . Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection . Journal of Gastroenterology vol. 54 , ( 8 ) 752 - 761 .

Harrison GI, Murray K, Gore R, Lee P, Sreedharan A, Richardson P, Hughes AJ, Wiselka M et al. ( 2019 ) . The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus‐infected people who inject drugs in England . Addiction vol. 114 , ( 6 ) 1113 - 1122 .

Foster GR, Asselah T, Kopecky-Bromberg S, Lei Y, Asatryan A, Trinh R, Zadeikis N, Mensa FJ ( 2019 ) . Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older . PLOS ONE vol. 14 , ( 1 )

Russell A, Hepgul N, Nikkheslat N, Borsini A, Zajkowska Z, Moll N, Forton D, Agarwal K et al. ( 2018 ) . Persistent fatigue induced by interferon-alpha: a novel, inflammation-based, proxy model of chronic fatigue syndrome . Psychoneuroendocrinology vol. 100 , 276 - 285 .

MADURASINGHE VW, ELDRIDGE S, GRIFFITHS C ( 2018 ) . Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial . The Lancet Gastroenterology & Hepatology

Foster GR, Dore GJ, Wang S, Grebely J, Sherman KE, Baumgarten A, Conway B, Jackson D et al. ( 2018 ) . Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies . Drug and Alcohol Dependence vol. 194 , 487 - 494 .

Williams R, Alexander G, Aspinall R, Batterham R, Bhala N, Bosanquet N, Severi K, Burton A et al. ( 2018 ) . Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK . The Lancet vol. 392 , ( 10162 ) 2398 - 2412 .

Vinikoor MJ, Sinkala E, Kanunga A, Muchimba M, Nsokolo B, Chilengi R, Wandeler G, Mulenga J et al. ( 2018 ) . Chronic hepatitis B virus monoinfection at a university hospital in Zambia . World Journal of Hepatology vol. 10 , ( 9 ) 622 - 628 .

Grebely J, Puoti M, Wedemeyer H, Cooper C, Sulkowski MS, Foster GR, Berg T, Villa E et al. ( 2018 ) . Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials . Open Forum Infectious Diseases vol. 5 , ( 11 )

Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, Spicer A, Badrock J et al. ( 2018 ) . Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score . The Lancet Gastroenterology & Hepatology vol. 3 , ( 9 ) 626 - 634 .

Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD et al. ( 2018 ) . Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial . Hepatology vol. 67 , ( 6 ) 2113 - 2126 .

Parry S, Bundle N, Ullah S, Foster GR, Ahmad K, Tong CYW, Balasegaram S, Orkin C ( 2018 ) . Implementing routine blood-borne virus testing for HCV, HBV and HIV at a London Emergency Department – uncovering the iceberg? . Epidemiology and Infection vol. 146 , ( 8 ) 1026 - 1035 .

Bridge S, Pagano S, Jones M, Foster G, Neely D, Vuilleumier N, Bassendine M ( 2018 ) . FRI-395 Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis? . Journal of Hepatology . vol. 68 , s539 - s540 .

Cheung M, Mutimer D, Agarwal K, Brown A, Aldersley M, Foster G, Irving W ( 2018 ) . LBP-009 Long term real life follow-up of patients with chronic hepatitis C virus and decompensated cirrhosis after direct acting antivirals – what is the clinical benefit of antiviral treatment? . Journal of Hepatology . vol. 68 , s109 - s110 .

Flanagan S, Appleby VJ, Gaviria J, Kunkel J, Madurasinghe V, Eldridge S, Moreea S, Agarwal K et al. ( 2018 ) . PS-093 HepFree: Screening migrant patients for viral hepatitis in primary care. A 90,000 patient randomised controlled trial indicates benefits are most obvious in older patients . Journal of Hepatology . vol. 68 , s51 - s52 .

Heath H, Kudo H, Renney G, Ward M, Cutillas P, Goldin RD, Hutchins R, Foster G et al. ( 2018 ) . SAT-018 The pathogenic role of Stat2 in inflammation is independent of canonical interferon signaling and is mediated by TNFa . Journal of Hepatology . vol. 68 ,

Podlaha O, Agarwal K, Thompson A, Foster G, Samuel D, Yatsuhashi H, Gaggar A, Kitrinos K et al. ( 2018 ) . SAT-379 Whole genome viral sequencing reveals subgenotype specific dynamics of antiviral treatment response in HBeAg positive and treatment naive chronic hepatitis B patients . Journal of Hepatology . vol. 68 , s778 - s779 .

Poordad F, Zeuzem S, Asatryan A, Foster G, Gane E, Wyles D, Stanislas P, Ferret MB et al. ( 2018 ) . THU-296 Glecaprevir/pibrentasvir in patients with hepatitis C and prior treatment experience: an integrated phase II/III analysis . Journal of Hepatology . vol. 68 ,

Puoti M, Foster GR, Wang S, Mutimer D, Gane E, Moreno C, Chang TT, Lee SS et al. ( 2018 ) . High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis . Journal of Hepatology vol. 69 , ( 2 ) 293 - 300 .

Brown A, Hézode C, Zuckerman E, Foster GR, Zekry A, Roberts SK, Lahser F, Durkan C et al. ( 2018 ) . Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C‐SCAPE study . Journal of Viral Hepatitis vol. 25 , ( 5 ) 457 - 464 .

Harris M, Bonnington O, Harrison G, Hickman M, Irving W, team TH ( 2018 ) . Understanding hepatitis C intervention success—Qualitative findings from the HepCATT study . Journal of Viral Hepatitis vol. 25 , ( 7 ) 762 - 770 .

Sinkala E, Zyambo K, Besa E, Kaonga P, Nsokolo B, Kayamba V, Vinikoor M, Zulu R et al. ( 2018 ) . Rifaximin Reduces Markers of Inflammation and Bacterial 16S rRNA in Zambian Adults with Hepatosplenic Schistosomiasis: A Randomized Control Trial . Am J Trop Med Hyg

Grebely J, Feld JJ, Wyles D, Sulkowski M, Ni L, Llewellyn J, Mir HM, Sajed N et al. ( 2018 ) . Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies . Open Forum Infectious Diseases vol. 5 , ( 2 )

Bridge SH, Pagano S, Jones M, Foster GR, Neely D, Vuilleumier N, Bassendine MF ( 2018 ) . Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis? . Hepatol Int vol. 12 , ( 1 ) 17 - 25 .

Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M et al. ( 2018 ) . Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection . New England Journal of Medicine vol. 378 , ( 4 ) 354 - 369 .

Nsokolo B, Kanunga A, Sinkala E, Zyambo K, Kumwenda D, Chama D, Muyinda G, Vinikoor M et al. ( 2018 ) . Stage of disease in hepatitis B virus infection in Zambian adults is associated with large cell change but not well defined using classic biomarkers . Trans R Soc Trop Med Hyg vol. 111 , ( 9 ) 425 - 432 .

da Silva Filipe A, Sreenu V, Hughes J, Aranday-Cortes E, Irving WL, Foster GR, Agarwal K, Rosenberg W et al. ( 2018 ) . Reply to: “Reply to: ‘Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries’” . Journal of Hepatology vol. 68 , ( 4 ) 864 - 866 .

KENNEDY P ( 2018 ) . Hepatitis B virus–specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation . Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation vol. 128 , ( 2 ) 668 - 681 .

Felizarta F, Asatryan A, Aguilar HI, Poordad F, Agarwal K, Nevens F, Hassanein TI, Foster GR et al. ( 2018 ) . Durability of Sustained Virologic Response and Liver Safety in Patients Treated with Glecaprevir/Pibrentasvir: A Long-Term Follow-up Study . HEPATOLOGY . vol. 68 , 358A - 358A .

Buti M, Fung SK, Ahn SH, Foster GR, Yang JC, Wang H, Flaherty JF, Gaggar A et al. ( 2018 ) . Loss of Hepatitis B e Antigen (HBeAg) during Nucleos(t)Ide (NUC) Therapy Is Associated with Greater Improvement in Liver Fibrosis . HEPATOLOGY . vol. 68 , 1201A - 1201A .

Dalgard O, Grebely J, Feld JJ, Wyles D, Sulkowski M, Ni L, Llewellyn J, Soyemi T et al. ( 2018 ) . Sofosbuvir-Based Direct-Acting Antiviral Therapies for Hcv in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies . HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS . vol. 20 , 13 - 14 .

Roberts SK, Buti M, Foster GR, Luis Calleja J, Sood A, Isakov VA, Ola R, Weiland H et al. ( 2018 ) . Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: An Integrated Analysis of Phase 2 and Phase 3 Clinical Trials . HEPATOLOGY . vol. 68 , 373A - 374A .

Heath H, Britton G, Kudo H, Renney G, Ward M, Goldin RD, Hutchins R, Foster GR et al. ( 2018 ) . Stat2 Deletion Impairs MAPK Signaling, NF-Kb Localisation to the Nucleus, Cytokine Expression and Is Protective from Sterile Inflammation . HEPATOLOGY . vol. 68 , 628A - 628A .

Foster G ( 2018 ) . Third-generation ventricular assist devices . Mechanical Circulatory and Respiratory Support ,

Younossi ZM, Stepanova M, Asselah T, Foster G, Patel K, Bräu N, Swain M, Tran T et al. ( 2017 ) . Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes . Clinical Infectious Diseases vol. 66 , ( 11 ) 1742 - 1750 .

Williams R, Alexander G, Armstrong I, Baker A, Bhala N, Camps-Walsh G, Cramp ME, de Lusignan S et al. ( 2017 ) . Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK . The Lancet vol. 391 , ( 10125 ) 1097 - 1107 .

Younossi ZM, Stepanova M, Jacobson IM, Asselah T, Gane EJ, Lawitz E, Foster GR, Roberts SK et al. ( 2017 ) . Sofosbuvir and velpatasvir with or without voxilaprevir in direct‐acting antiviral‐naïve chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3 . Alimentary Pharmacology & Therapeutics vol. 47 , ( 2 ) 259 - 267 .

De Silva S, Li W, Kemos P, Brindley JH, Mecci J, Samsuddin S, Chin-Aleong J, Feakins RM et al. ( 2017 ) . Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent . Frontline Gastroenterology vol. 9 , ( 2 )

Foster G ( 2017 ) . Editorial for “Supplement on Optimal Therapy for Chronic Hepatitis B in China” . Journal of Viral Hepatitis vol. 24 , ( S1 ) 3 - 3 .

Asselah T, Bourgeois S, Pianko S, Zeuzem S, Sulkowski M, Foster GR, Han L, McNally J et al. ( 2017 ) . Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1‐6 and compensated cirrhosis or advanced fibrosis . Liver International vol. 38 , ( 3 ) 443 - 450 .

Bernstein DE, Foster G, Dylla D, Mauss S, Nelson D, Asselah T, Flamm S, Cooper C et al. ( 2017 ) . Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir to Treat HCV Genotype 1-6 Infection in Patients Without Cirrhosis Including HIV Co-Infection . The American Journal of Gastroenterology . vol. 112 , s490 - s491 .

Shafran SD, Shaw D, Charafeddine M, Agarwal K, Foster GR, Abunimeh M, Pilot‐Matias T, Pothacamury RK et al. ( 2017 ) . Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III) . Journal of Viral Hepatitis vol. 25 , ( 2 ) 118 - 125 .

Gane EJ, Pianko S, Roberts SK, Thompson AJ, Zeuzem S, Zuckerman E, Ben-Ari Z, Foster GR et al. ( 2017 ) . Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials . The Lancet Gastroenterology & Hepatology vol. 2 , ( 11 ) 805 - 813 .

da Silva Filipe A, Sreenu V, Hughes J, Aranday-Cortes E, Irving WL, Foster GR, Agarwal K, Rosenberg W et al. ( 2017 ) . Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries . Journal of Hepatology vol. 67 , ( 6 ) 1348 - 1350 .

Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, Hickman M, Hellard M et al. ( 2017 ) . Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs . International Journal of Drug Policy vol. 47 , 51 - 60 .

Heath H, Renney G, Ward M, Cutillas P, Kudu H, Goldin R, Hutchins R, Foster G et al. ( 2017 ) . OC-080 Stat2 is a key mediator of acute pancreatitis . Gut . vol. 66 ,

Poordad F, Nelson DR, Feld JJ, Fried MW, Wedemeyer H, Larsen L, Cohen DE, Cohen E et al. ( 2017 ) . Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis – A pooled analysis . Journal of Hepatology vol. 67 , ( 4 ) 700 - 707 .

Midgard H, Hajarizadeh B, Cunningham EB, Conway B, Backmund M, Bruggmann P, Bruneau J, Bourgeois S et al. ( 2017 ) . Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study . International Journal of Drug Policy vol. 47 , 230 - 238 .

De Silva S, Li W, Kemos P, Brindley J, Mecci J, Samsuddin S, Chin-Aleong J, Feakins R et al. ( 2017 ) . PWE-075 Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of south asian descent . Gut . Conference: Liver vol. 66 ,

Grebely J, Dalgard O, Cunningham EB, Hajarizadeh B, Foster GR, Bruggmann P, Conway B, Backmund M et al. ( 2017 ) . Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study . International Journal of Drug Policy vol. 47 , 177 - 186 .

Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, Bruggmann P, Conway B et al. ( 2017 ) . Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study . BMC Infect Dis vol. 17 , ( 1 ) 420 - 420 .

Jones M, Cunningham ME, Wing P, DeSilva S, Challa R, Sheri A, Padmanabhan S, Iyer RP et al. ( 2017 ) . SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants . Journal of Medical Virology vol. 89 , ( 9 ) 1620 - 1628 .

Lamoury FMJ, Soker A, Martinez D, Hajarizadeh B, Cunningham EB, Cunningham P, Bruggmann P, Foster GR et al. ( 2017 ) . Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse . Journal of Clinical Virology vol. 92 , 32 - 38 .

Robaeys G, Christensen S, Lucidarme D, Arain A, Bruggmann P, Kunkel J, Keim S, Jäkel M et al. ( 2017 ) . Chronic Hepatitis C Treatment in Patients with Drug Injection History: Findings of the INTEGRATE Prospective, Observational Study . Infectious Diseases and Therapy vol. 6 , ( 2 ) 265 - 275 .

Ansari MA, Pedergnana V, L C Ip C, Magri A, Von Delft A, Bonsall D, Chaturvedi N, Bartha I et al. ( 2017 ) . Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus . Nature Genetics vol. 49 , ( 5 ) 666 - 673 .

Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, Borgia SM, Shafran SD et al. ( 2017 ) . Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials . Gastroenterology vol. 153 , ( 1 ) 113 - 122 .

Mangia A, Foster GR, Berg CP, Curescu M, Ledinghen VD, Habersetzer F, Manolakopoulos S, Negri E et al. ( 2017 ) . Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study . Annals of Gastroenterology vol. 30 , ( 3 ) 327 - 343 .

Feld JJ, Foster GR ( 2017 ) . Corrigendum to “Second generation direct-acting antivirals – do we expect major improvements?” . Journal of Hepatology vol. 66 , ( 5 )

McLauchlan J, Innes H, Dillon JF, Foster G, Holtham E, McDonald S, Wilkes B, Hutchinson SJ et al. ( 2017 ) . Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank . International Journal of Epidemiology vol. 46 , ( 5 ) 1391 - 1391h .

Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Sanai F et al. ( 2017 ) . Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response . PLoS One vol. 12 , ( 1 ) e0168713 - e0168713 .

Lawitz E, Gane EJ, Feld JJ, Buti M, Foster GR, Rabinovitz M, Burnevich EZ, Katchman H et al. ( 2017 ) . C-BREEZE 2: Efficacy and Safety of a Two-Drug Direct-Acting Antiviral Agent (DAA) Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Genotype (GT) 1, 2, 3, 4, or 6 . HEPATOLOGY . vol. 66 , 34A - 35A .

Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD et al. ( 2017 ) . FRI-213 Elbasvir/grazoprevir plus sofosbuvir in treatment-naive and treatment-experienced cirrhotic patients with hepatitis C virus genotype 3 infection treated for 8, 12, or 16 weeks: final results of the C-ISLE study . Journal of Hepatology . vol. 66 , s503 - s504 .

Irving WL, McLauchlan J, Foster G, UK HR ( 2017 ) . FRI-214 Real world outcomes of DAA therapy for chronic hepatitis C virus infection in the HCV Research UK National cohort . Journal of Hepatology . vol. 66 ,

Foster G, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD et al. ( 2017 ) . FRI-215 Successful treatment of patients with HCV GT3 infection and cirrhosis with elbasvir/grazoprevir plus sofosbuvir does not correct insulin resistance by 12 weeks post-treatment . Journal of Hepatology . vol. 66 , s504 - s505 .

Grebley J, Puoti M, Wedemeyer H, Cooper C, Sulkowski MS, Foster G, Berg T, Villa E et al. ( 2017 ) . FRI-236 Safety and efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials . Journal of Hepatology . vol. 66 ,

Foster GR, Gane E, Asatryan A, Asselah T, Ruane PJ, Pol S, Poordad F, Stedman CA et al. ( 2017 ) . GS-007 ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis . Journal of Hepatology . vol. 66 ,

Flanagan S, Appleby VJ, Gaviria J, Madurasinghe V, Kunkel J, Eldridge S, Moreea S, Agarwal K et al. ( 2017 ) . HepFree: A large cluster randomised controlled cross sectional trial to assess screening and treating first and second generation migrants from 'At Risk' countries with chronic viral hepatitis . HEPATOLOGY . vol. 66 , 550A - 551A .

Younossi ZM, Stepanova M, Asselah T, Foster GR, Patel K, Brau N, Swain MG, Tran TT et al. ( 2017 ) . Hepatitis C (HCV) in Patients Without Fibrosis or with Minimal Fibrosis: The Impact of Treatment and Sustained Virologic Response (SVR) on Patient-Reported Outcomes (PROs) . HEPATOLOGY . vol. 66 , 526A - 526A .

Puoti M, Foster G, Wang S, Mutimer D, Gane E, Moreno C, Chang TT, Lee S et al. ( 2017 ) . High SVR Rates with 8 and 12 Weeks of Pangenotypic Glecaprevir/Pibrentasvir: Integrated Efficacy and Safety Analysis of Genotype 1-6 Patients without Cirrhosis . SWISS MEDICAL WEEKLY . vol. 147 , 20S - 20S .

Marshall AD, Nielsen S, Cunningham EB, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O et al. ( 2017 ) . LBP-505 Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe . Journal of Hepatology . vol. 66 , s95 - s96 .

Charlton M, Cheung MCM, Manns M, Sajed N, Troke PJF, Spellman J, Copans A, Arterburn S et al. ( 2017 ) . Ledipasvir/Sofosbuvir plus Ribavirin (LDV/SOF+RBV) for 12 Weeks in Decompensated HCV Genotype 1 Patients: SOLAR-1 and SOLAR-2 Studies Compared to a Real-world Dataset . TRANSPLANTATION . vol. 101 , 92 - 92 .

Cheung MC, Filipe A, Walker A, Mutimer DJ, Agarwal K, Aldersley M, MacDonald D, Khakoo S et al. ( 2017 ) . PS-158 Re-treatment of patients with decompensated chronic hepatitis C virus cirrhosis using 24 weeks of sofosbuvir and NS5A inhibitor, with or without ribavirin after failing a 12 week course . Journal of Hepatology . vol. 66 , s84 - s85 .

Foster GR, Wing P, Jones M, Lee W-YJ, Cheung MC, McLauchlan J, daSilva-Filipe A, Irving W et al. ( 2017 ) . Polymorphisms in the genotype 3 hepatitis C virus polymerase protein modify the response to interferon and sofosbuvir . HEPATOLOGY . vol. 66 , 1270A - 1270A .

El-Sherif O, Pertinez H, Irving W, Penchala SD, McLauchlan J, Foster GR, Norris S, Else L et al. ( 2017 ) . Population pharmacokinetic analysis of ledipasvir in patients with decompensated cirrhosis - results from the UK Expanded Access programme . HEPATOLOGY . vol. 66 , 831A - 832A .

Holland-Fischer P, Shah N, Sawhney R, Privitera G, Spinella S, Masson S, Foster G, Aithal G et al. ( 2017 ) . SAT-022 DASIMAR: a novel prognostic biomarker for acute cirrhosis decompensation to guide early intervention - a prospective multicenter study . Journal of Hepatology . vol. 66 ,

Le Bert N, Rivino L, Gill US, Cheng Y, Kunasegaran K, Tan DZ, Becht E, Hansi NK et al. ( 2017 ) . SAT-152 PD-1+ CD8+ T cells as immunological biomarkers for the safe discontinuation of anti-viral therapy in chronic hepatitis B . Journal of Hepatology . vol. 66 ,

Puoti M, Foster G, Wang S, Mutimer D, Gane E, Moreno C, Chang TT, Lee SS et al. ( 2017 ) . SAT-233 High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1–6 patients without cirrhosis . Journal of Hepatology . vol. 66 ,

De Silva S, Li W, Kemos P, Brindley JH, Feakins R, Chinaleong J, Samsuddin S, Foster GR et al. ( 2017 ) . SAT-320 Blood-test based assessment of liver fibrosis, but not transient elastography, is less accurate in NAFLD patients of South Asian compared to White ethnicity . Journal of Hepatology . vol. 66 , s595 - s596 .

Macken L, Verma S, Foster GR, McLauchlan J, Irving W ( 2017 ) . Safety and Efficacy of Direct Acting Antivirals: UK Real World Experience from a Large Well Characterised Predominantly Cirrhotic HCV Cohort . HEPATOLOGY . vol. 66 , 592A - 593A .

Foster GR, Kopecky-Bromberg S, Lei Y, Mensa FJ ( 2017 ) . Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients Aged 65 Years or Older With Chronic Hepatitis C: A Pooled Analysis of Phase 2 and 3 Clinical Trials . HEPATOLOGY . vol. 66 , 640A - 641A .

Foster GR, Grebely J, Sherman KE, Wang S, Dore GJ, Baumgarten A, Conway B, Jackson DFIII et al. ( 2017 ) . Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1-6 and Recent Drug Use . HEPATOLOGY . vol. 66 , 636A - 637A .

Vinaixa C, Foster G, Coilly A, Belli L, Mix H, Duvoux C, Berenguer M ( 2017 ) . Safety and Efficacy of Interferon-free Antiviral Treatment in Patients with MELD over 20 . TRANSPLANTATION . vol. 101 , 92 - 93 .

Sulkowski M, Foster G, Shiffman M, Byrne S, Wolf J, Grabowski C, McNally J, Brainard D et al. ( 2017 ) . Safety and efficacy of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C in patients aged 65 years or older: a retrospective analysis of phase 3 studies . JOURNAL OF HEPATOLOGY . vol. 66 , S719 - S719 .

Feld JJ, Foster GR ( 2017 ) . Second generation direct-acting antivirals - do we expect major improvements? (vol 66, pg s130, 2016) . JOURNAL OF HEPATOLOGY vol. 66 , ( 5 ) 1105 - 1105 .

Foster GR ( 2016 ) . Chronic hepatitis C: less of a problem than first thought? . The Lancet Gastroenterology & Hepatology vol. 2 , ( 3 ) 146 - 147 .

Williams R, Alexander G, Aspinall R, Bosanquet J, Camps-Walsh G, Cramp M, Day N, Dhawan A et al. ( 2016 ) . New metrics for the Lancet Standing Commission on Liver Disease in the UK . The Lancet vol. 389 , ( 10083 ) 2053 - 2080 .

Hézode C, Fried MW, Colombo M, Bourlière M, Spengler U, Ben-Ari Z, Strasser SI, Perumalswami P et al. ( 2016 ) . Efficacy and Safety of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Virus Infection and Inherited Blood Disorders: Final Data from the C-Edge Ibld Study . Blood . vol. 128 ,

Mangia A, De Ledinghen V, Bailly F, Brahm J, Keiss J, Valantinas J, Rasmann N, Messinger D et al. ( 2016 ) . IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study . Springerplus vol. 5 , ( 1 ) 1990 - 1990 .

Younossi ZM, Stepanova M, Feld J, Zeuzem S, Sulkowski M, Foster GR, Mangia A, Charlton M et al. ( 2016 ) . Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis . Clinical Gastroenterology and Hepatology vol. 15 , ( 3 ) 421 - 430.e6 .

Lewis H, Kunkel J, Axten D, Dalton J, Gardner H, Tippett A, Wynne S, Wilkinson M et al. ( 2016 ) . Community nurse-led initiation of antiviral therapy for chronic hepatitis C in people who inject drugs does not increase uptake of or adherence to treatment . Eur J Gastroenterol Hepatol vol. 28 , ( 11 ) 1258 - 1263 .

Feld JJ, Foster GR ( 2016 ) . Second generation direct-acting antivirals – Do we expect major improvements? . Journal of Hepatology vol. 65 , ( 1 ) s130 - s142 .

Marcellin P, Ahn SH, Chuang W-L, Hui AJ, Tabak F, Mehta R, Petersen J, Lee C-M et al. ( 2016 ) . Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa‐2a combination therapy for chronic hepatitis B . Alimentary Pharmacology & Therapeutics vol. 44 , ( 9 ) 957 - 966 .

Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, McNally J, Osinusi A et al. ( 2016 ) . Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials . Clinical Infectious Diseases vol. 63 , ( 11 ) 1479 - 1481 .

Foster GR, Chayama K, Chuang W-L, Fainboim H, Farkkila M, Gadano A, Gaeta GB, Hézode C et al. ( 2016 ) . A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3 . Springerplus vol. 5 , ( 1 ) 1365 - 1365 .

Gill US, Peppa D, Micco L, Singh HD, Carey I, Foster GR, Maini MK, Kennedy PTF ( 2016 ) . Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo . PLOS Pathogens vol. 12 , ( 8 ) e1005788 - e1005788 .

Younossi ZM, Stepanova M, Sulkowski M, Foster GR, Reau N, Mangia A, Patel K, Bräu N et al. ( 2016 ) . Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials . Clinical Infectious Diseases vol. 63 , ( 8 ) 1042 - 1048 .

Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Ryan R et al. ( 2016 ) . An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1) . PLoS One vol. 11 , ( 7 ) e0158526 - e0158526 .

Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, Brown A, Gelson WTH et al. ( 2016 ) . Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis . Journal of Hepatology vol. 65 , ( 4 ) 741 - 747 .

Martin NK, Vickerman P, Dore GJ, Grebely J, Miners A, Cairns J, Foster GR, Hutchinson SJ et al. ( 2016 ) . Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation . Journal of Hepatology vol. 65 , ( 1 ) 17 - 25 .

Pieper IL, Radley G, Chan CHH, Friedmann Y, Foster G, Thornton CA ( 2016 ) . Quantification methods for human and large animal leukocytes using DNA dyes by flow cytometry . Cytometry Part A vol. 89 , ( 6 ) 565 - 574 .

Hewett N, Buchman P, Musariri J, Sargeant C, Johnson P, Abeysekera K, Grant L, Oliver EA et al. ( 2016 ) . Randomised controlled trial of GP-led in-hospital management of homeless people ('Pathway) . Clinical Medicine vol. 16 , ( 3 ) 223 - 229 .

Orkin C, Jeffery-Smith A, Foster GR, Tong CYW ( 2016 ) . Retrospective hepatitis C seroprevalence screening in the antenatal setting—should we be screening antenatal women? . BMJ Open vol. 6 , ( 5 ) e010661 - e010661 .

Li H, Chen L-Y, Zhang N-N, Li S-T, Zeng B, Pavesi M, Amorós À, Mookerjee RP et al. ( 2016 ) . Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis B . Scientific Reports vol. 6 , 25487 - 25487 .

Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P, Yoshida EM et al. ( 2016 ) . Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials . Ann Hepatol vol. 15 , ( 3 ) 333 - 349 .

( 2016 ) . Department of Error . The Lancet vol. 387 , ( 10030 )

Foster GR ( 2016 ) . Reply to: “High mortality during direct acting antiviral therapy for hepatitis C patients with Child’s C cirrhosis: Results of the Irish Early Access Programme” . Journal of Hepatology

Foster GR, Mangia A, Sulkowski M ( 2016 ) . Sofosbuvir and Velpatasvir for Patients with HCV Infection . New England Journal of Medicine vol. 374 , ( 17 ) 1687 - 1689 .

Jensen D, Asselah T, Dieterich D, Foster G, Sulkowski M, Zeuzem S, Mantry P, Yoshida E et al. ( 2016 ) . Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials . Annals of Hepatology vol. 15 , ( 3 ) 333 - 349 .

Foster GR, Coppola C, Derbala M, Ferenci P, Orlandini A, Reddy KR, Tallarico L, Shiffman ML et al. ( 2016 ) . Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort . PLoS One vol. 11 , ( 3 ) e0151703 - e0151703 .

Orkin C, Flanagan S, Wallis E, Ireland G, Dhairyawan R, Fox J, Nandwani R, O'Connell R et al. ( 2016 ) . Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: the “Going Viral” campaign . HIV Medicine vol. 17 , ( 3 ) 222 - 230 .

Vergis N, Khamri W, Beale K, Sadiq F, Aletrari MO, Moore C, Atkinson SR, Bernsmeier C et al. ( 2016 ) . Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase . Gut vol. 66 , ( 3 )

Cheung M, Foster G, Irving W, McLauchlan J, Walker A, Hudson B, Verma S, Agarwal K ( 2016 ) . Antiviral treatment in patients with advanced hepatitis C virus cirrhosis with sofosbuvir and either ledipasvir or daclatasvir, with or without ribavirin: observational cohort study . The Lancet . vol. 387 ,

Foster GR, Irving WL, Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ et al. ( 2016 ) . Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis . Journal of Hepatology vol. 64 , ( 6 ) 1224 - 1231 .

Foster GR, Agarwal K, Cramp M, Moreea S, Barclay ST, Collier J, Brown AS, Ryder SD et al. ( 2016 ) . C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naive and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks . HEPATOLOGY . vol. 64 , 39A - 40A .

Verma S, Foster GR, Sadler MD, Heneghan MA, Irving W, Considine AB, Childs K, Suddle A et al. ( 2016 ) . Decreased health resource utilization by peri-transplant (PT) HCV patients after successful direct acting antiviral (DAA) therapy . HEPATOLOGY . vol. 64 , 459A - 460A .

Marcellin P, Xie Q, Paik SW, Flisiak R, Piratvisuth T, Petersen J, Asselah T, Cornberg M et al. ( 2016 ) . FRI-137 Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study . Journal of Hepatology . vol. 64 , s598 - s599 .

Wei L, Pavlovic V, Bansal AT, Chen X-P, Foster GR, He H, Kao J-H, Lampertico P et al. ( 2016 ) . FRI-146 Genetic Variation in FCER1A Gene Predicts Sustained HBsAg Clearance in East-Asian Patients Treated with Pegylated Interferon Alfa-2a (40kd): The “Peg-Be-Yond” Study . Journal of Hepatology . vol. 64 ,

Lawitz EJ, Ruane P, Stedman C, Foster G, Hyland RH, Coogan S, Moody S, Dvory-Sobol H et al. ( 2016 ) . FRI-166 Long-Term Follow-Up of Patients with Chronic HCV Infection following Treatment with Direct Acting Antiviral Regimens: Maintenance of SVR, Persistence of Resistance Mutations and Clinical Outcomes . Journal of Hepatology . vol. 64 , s612 - s613 .

Lamoury F, Soker A, Martinez D, Hajarizadeh B, Cunningham E, Bruggmann P, Foster G, Dalgard O et al. ( 2016 ) . FRI-195 Hepatitis C Virus Core Antigen: A Simplified Treatment Monitoring Tool, including for Post-Treatment Relapse . Journal of Hepatology . vol. 64 , s625 - s626 .

Martin NK, Vickerman P, Dore GJ, Grebely J, Miners A, Cairns J, Foster GR, Hutchinson SJ et al. ( 2016 ) . FRI-420 Comparing Individual and Population Prevention Benefits of Early Direct-Acting Antiviral Treatment for HCV . Journal of Hepatology . vol. 64 ,

Welzel TM, Kwo PY, Jacobson IM, Zhang J, De-Oertel S, McNally J, Brainard DM, McHutchison JG et al. ( 2016 ) . Factors Associated with Persistent Alanine Aminotransferase Elevation in Patients Treated with Ledipasvir/Sofosbuvir or Sofosbuvir/Velpatasvir . HEPATOLOGY . vol. 64 , 449A - 449A .

Ansari MA, Pedergnana V, Bonsall D, Chaturvedi N, Bartha I, Fellay J, Smith D, Bowden R et al. ( 2016 ) . GENOME-TO-GENOME VIRUS-HOST ANALYSIS REVEALS HCV GENOTYPE 3 VIRAL POLYMORPHISMS LINKED VIRAL LOADAND TO HOST HLA CLASS-I/II AND IL28B ALLELES . JOURNAL OF HEPATOLOGY . vol. 64 , S419 - S419 .

Tran TT, Feld JJ, Foster GR, Naik S, Eggleton ES, Zhang J, Natha M, Llewellyn J et al. ( 2016 ) . Gender Differences in Patients Treated for HCV: Efficacy and Safety of Sofosbuvir/Velpatasvir in Women . HEPATOLOGY . vol. 64 , 422A - 422A .

Marcellin P, Seto W-K, Hu C-T, Yurdaydin C, Foster GR, Flaherty JF, Kim K, Suri V et al. ( 2016 ) . Genotype Specific Differences In Magnitude Of HBsAg Reduction During TDF or tenofovir alfenamide (TAF) Therapy In CHB Patients . HEPATOLOGY . vol. 64 , 918A - 918A .

Younossi ZM, Stepanova M, Feld J, Zeuzem S, Sulkowski M, Foster GR, Mangia A, Charlton M et al. ( 2016 ) . IMPRESSIVE GAINS IN PATIENT-REPORTED OUTCOMES ARE OBSERVED IN CHRONIC HEPATITIS C PATIENTS WITH OR WITHOUT CIRRHOSIS WHO ARE TREATED WITH SOFOSBUVIR AND VELPATASVIR: RESULTS FROM ASTRAL-1,-2,-3 AND-4 . JOURNAL OF HEPATOLOGY . vol. 64 , S629 - S629 .

Charlton MR, Cheung MC, Manns MP, Sajed N, Troke P, Spellman JG, Copans A, Arterburn S et al. ( 2016 ) . Ledipasvir/Sofosbuvir plus Ribavirin (LDV/SOF+RBV) for 12 Weeks in Decompensated HCV Genotype 1 Patients: SOLAR-1 and-2 Studies Compared to a Real-World Dataset . HEPATOLOGY . vol. 64 , 489A - 490A .

Iser D, Lawitz EJ, Ruane P, Stedman C, Foster G, Mir HM, Hyland RH, Coogan S et al. ( 2016 ) . Long-term follow-up of patients with chronic HCV infection following treatment with direct acting antiviral regimens: maintenance of SVR, persistence of resistance mutations, and clinical outcomes . JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY vol. 31 , 74 - 75 .

Rivino L, Le Bert N, Gill U, Cheng Y, Kunasegaran K, Tan D, Koh S, Hansi N et al. ( 2016 ) . PS056 An Immunological Biomarker to Predict Hepatic Flares upon Nuc Therapy Discontinuation in Chronic Hepatitis B . Journal of Hepatology . vol. 64 , s164 - s165 .

Cheung MCM, Foster GR, Irving WL, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ et al. ( 2016 ) . PS097 Antiviral Treatment in Patients with Advanced Hcv Cirrhosis Using Sofosbuvir and Ledipasvir/Daclatasvir with or without Ribavirin - 6 and 12 Month Outcomes Compared to Untreated Patients . Journal of Hepatology . vol. 64 , s185 - s186 .

Shafran S, Shaw D, Charafeddine M, Agarwal K, Foster GR, Abunimeh M, Fu B, Pilot-Matias T et al. ( 2016 ) . QUARTZ II-III: Final Efficacy and Safety Results in Patients with HCV Genotype 2 or 3 Infection Treated With Ombitasvir/Paritaprevir/Ritonavir and Sofosbuvir With or Without Ribavirin . HEPATOLOGY . vol. 64 , 440A - 440A .

Gane EJ, Pianko S, Roberts SK, Thompson AJ, Zeuzem S, Zuckerman E, Ari ZB, Foster GR et al. ( 2016 ) . SAT-139 High Efficacy of an 8-Week 3-Drug Regimen of Grazoprevir/MK-8408/MK-3682 in HCV Genotype 1, 2 and 3-Infected Patients: SVR24 Data from the Phase 2 C-Crest 1 and 2 Studies . Journal of Hepatology . vol. 64 ,

Jacobson I, Brau N, Bourgeois S, Mathurin P, Thuluvath P, Fessel WJ, Ryder S, Gerken G et al. ( 2016 ) . SAT-168 The Tolerability of SOF/VEL for 12 Weeks in >1,000 Patients Treated in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies: An Integrated Safety Analysis . Journal of Hepatology . vol. 64 , s773 - s774 .

Agarwal K, Schultz M, Pianko S, Bank L, Collier J, George J, Priest M, Ryder SD et al. ( 2016 ) . Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin . HEPATOLOGY . vol. 64 , 455A - 456A .

Foster GR, Zeuzem S, Gane EJ, Stedmar CA, Feld JJ, Mangia A, Agarwal K, Swain MG et al. ( 2016 ) . Sofosbuvir-Based All-Oral Regimens for Patients with Chronic Hepatitis C Genotype 3 Infection: Integrated Analysis of Five Clinical Studies . HEPATOLOGY . vol. 64 , 955A - 956A .

Younossi ZM, Stepanova M, Feld JJ, Zeuzem S, Sulkowski MS, Foster GR, Mangia A, Charlton MR et al. ( 2016 ) . Sofosbuvir/Velpatasvir (SOF/VEL)-Based Regimens are Associated with Excellent Efficacy and a Significant Improvement of Patients-Reported Outcomes (PROs) across Patient Populations: From Non-Cirrhotics to Compensated Cirrhotics to Decompensated Cirrhotics . HEPATOLOGY . vol. 64 , 12A - 12A .

Wing P, Filipe A, Cunningham ME, De Silva S, Cheung M, Jones M, Irving W, McLauchlan J et al. ( 2016 ) . THU-235 Pre-Treatment Reduction in Sensitivity to Sofosbuvir and Ribavirin in Patients with Genotype 3 Hepatitis C Virus who Relapse following all Oral Antiviral Therapy . Journal of Hepatology . vol. 64 , s407 - s408 .

Foster G, Gane E, Asatryan A, Pol S, Poordad F, Vierling J, Kort J, Lin C-W et al. ( 2016 ) . THU-482 Endurance-3: A Phase 3, Randomized, Open-Label, Active-Controlled Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with HCV Genotype 3 Infection . Journal of Hepatology . vol. 64 ,

Foster GR ( 2015 ) . The Journal Of Viral Hepatitis 2016 . Journal of Viral Hepatitis vol. 23 , ( 1 ) 4 - 4 .

Williams R, Ashton K, Aspinall R, Bellis MA, Bosanquet J, Cramp ME, Day N, Dhawan A et al. ( 2015 ) . Implementation of the Lancet Standing Commission on Liver Disease in the UK . The Lancet vol. 386 , ( 10008 ) 2098 - 2111 .

Foster GR, Ferenci P, Asselah T, Mantry P, Dufour J-F, Bourlière M, Forton D, Maevskaya M et al. ( 2015 ) . Open‐label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1‐infected patients who failed placebo plus peginterferon and ribavirin . Journal of Viral Hepatitis vol. 23 , ( 3 ) 227 - 231 .

Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A et al. ( 2015 ) . Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection . New England Journal of Medicine vol. 373 , ( 27 ) 2608 - 2617 .

Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, Chuang W-L, Lim S-G et al. ( 2015 ) . Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B . Gastroenterology vol. 150 , ( 1 ) 134 - 144.e10 .

Orkin C, Leach E, Flanagan S, Wallis E, Ruf M, Foster GR, Tong CYW ( 2015 ) . High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: Should we be screening for HCV in ED attendees? . Epidemiology and Infection vol. 143 , ( 13 ) 2837 - 2840 .

Pawlotsky J, Flisiak R, Sarin SK, Rasenack J, Piratvisuth T, Chuang W, Peng C, Foster GR et al. ( 2015 ) . Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection . Hepatology vol. 62 , ( 4 ) 1013 - 1023 .

Ghani R, Javaid A, Marley R, Lindsay J, Kennedy PT, Foster GR ( 2010 ) . PWE-047 Evaluation of PEG-IFN in an ethnically diverse HBV-infected population: 50% of treated patients derive long-term benefit . Gut . vol. 59 ,

Dyson JK, Hutchinson J, Harrison L, Rotimi O, Tiniakos D, Foster GR, Aldersley MA, McPherson S ( 2015 ) . Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use . Journal of Hepatology vol. 64 , ( 1 ) 234 - 238 .

Foster GR, Pianko S, Brown A, Forton D, Nahass RG, George J, Barnes E, Brainard DM et al. ( 2015 ) . Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection . Gastroenterology vol. 149 , ( 6 ) 1462 - 1470 .

Sinkala E, Kapulu MC, Besa E, Zyambo K, Chisoso NJ, Foster GR, Kelly P ( 2015 ) . Hepatosplenic schistosomiasis is characterised by high blood markers of translocation, inflammation and fibrosis . Liver International vol. 36 , ( 1 ) 145 - 150 .

Chan HL-Y, Elkhashab M, Trinh H, Tak WY, Ma X, Chuang W-L, Kim YJ, Martins EB et al. ( 2015 ) . Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B . Journal of Hepatology vol. 63 , ( 5 ) 1086 - 1092 .

Tai D, Lewis H, Derwa Y, Lillis A, Reynolds T, Maitland K, Hall D, Alazawi W et al. ( 2015 ) . PTH-093 One year mortality outcomes of patients with liver cirrhosis admitted to a teaching hospital intensive care unit . Gut . vol. 64 ,

Alazawi W, Heath H, Petts G, Kudu H, Feakins R, O’Brien A, Goldin R, Foster G ( 2015 ) . PTH-102 Stat2 is a key inflammatory molecule in human non-alcoholic fatty liver disease and murine liver injury . Gut . vol. 64 ,

Foster G, Asselah T, Moreno C, Sarrazin C, Gschwantler M, Craxi A, Buggisch P, Ryan R et al. ( 2015 ) . PTH-137 Safety and efficacy of simeprevir (SMV) plus PEG-IFN/RBV in treatment-naÏve chronic hepatitis c genotype 1 patients eligible for 12 weeks of treatment . Gut . vol. 64 ,

Rivino L, Van Den Berg M, Gill, Le Bert N, Koh S, Hansi N, Newell E, Foster G et al. ( 2015 ) . PTU-103 Characterisation of the immune profile in chronic hepatitis b patients following nucleos(t)ide discontinuation by cytof mass cytometry . Gut . vol. 64 ,

Hansi N, Gill, Banerjee M, Naik S, Tong W, Foster G, Carey I, Kennedy P ( 2015 ) . PTU-106 Identifying true immune-tolerant disease in children and young adults with chb using quantified hepatitis b surface antigen levels . Gut . vol. 64 ,

Hansi N, Gill, Banerjee M, Naik S, Tong W, Foster G, Carey I, Kennedy P ( 2015 ) . PTU-107 Defining the low-risk inactive carrier in chronic hepatitis b with qhbsag: do the same rules apply in children and young adults? . Gut . vol. 64 ,

Gill, Peppa D, Micco L, Singh H, Foster G, Maini M, Kennedy P ( 2015 ) . PTU-116 Functional immune restoration correlates with HBSAG decline and may predict treatment response on sequential NUC therapy in CHB . Gut . vol. 64 ,

Gill, Hansi N, Payaniandy L, Schulz J, Payaniandy D, Alazawi W, Dearden J, Kallis Y et al. ( 2015 ) . PTU-117 Sequential NUC therapy following pegylated interferon provides a greater decline in HBSAG and potentially offers a treatment advantage over current therapies . Gut . vol. 64 ,

Cunningham ME, Javaid A, Waters J, Davidson-Wright J, Wong JLC, Jones M, Foster GR ( 2015 ) . Development and validation of a "capture-fusion" model to study drug sensitivity of patient-derived hepatitis C . Hepatology vol. 61 , ( 4 ) 1192 - 1204 .

Foster GR, Pianko S, Cooper C, Brown A, Forton D, Nahass RG, George J, Barnes E et al. ( 2015 ) . LO5 : Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: The boson study . Journal of Hepatology . vol. 62 , s259 - s260 .

Foster GR, McLauchlan J, Irving W, Cheung M, Hudson B, Verma S, Agarwal K, Group HRUE ( 2015 ) . O002 : Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3 . Journal of Hepatology . vol. 62 , s190 - s191 .

Chan HL, Ahn SH, Chuang WL, Hui AJ, Tabak F, Mehta R, Petersen J, Lee C-M et al. ( 2015 ) . O117 : Predictors of clinical response: Results from a large, randomized controlled study with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB) . Journal of Hepatology . vol. 62 , s251 - s252 .

Lahiri R, Derwa Y, Bashir Z, Giles E, Torrance H, O’Dwyer M, Owen H, O’Brien A et al. ( 2015 ) . P0001 : Early monocyte dysfunction in patients who develop Systemic Inflammatory Response Syndrome (SIRS) and sepsis after hepatopancreaticobiliary surgery . Journal of Hepatology . vol. 62 , s290 - s291 .

Rivino L, Van Den Berg M, Le Bert N, Koh S, Gill US, Hansi NK, Foster GR, Bertoletti A et al. ( 2015 ) . P0474 : Characterisation of the immune profiles of chronic hepatitis B patients following NUC discontinuation by cyTOF mass cytometry . Journal of Hepatology . vol. 62 ,

Gill US, Peppa D, Micco L, Singh HD, Foster GR, Maini MK, Kennedy PT ( 2015 ) . P0485 : Functional immune restoration correlates with HBsAg decline and may predict treatment response on sequential NUC therapy in chronic hepatitis B . Journal of Hepatology . vol. 62 ,

Cunningham ME, Wing P, DeSilva S, Davidson-Wright J, Jones M, Foster GR ( 2015 ) . P0703 : Pre-treatment ribavirin sensitivity correlates with treatment outcome in genotype 3 HCV . Journal of Hepatology vol. 62 ,

Vermehren J, Perner D, Clark D, Susser S, Hubb J, Zeuzem S, Foster G, Sarrazin C ( 2015 ) . P0727 : Clinical utility of the artus HCV QS-RGQ assay for HCVRNA quantification . Journal of Hepatology . vol. 62 ,

Brown A, Hezode C, Zuckerman E, Foster G, Zekry A, Roberts S, Howe A, Durkan C et al. ( 2015 ) . P0771 : C-SCAPE: Efficacy and safety of 12 weeks of grazoprevir +/- elbasvir +/- ribavirin in patients with HCV GT2, 4, 5 or 6 infection . Journal of Hepatology . vol. 62 ,

Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxi A, Buggisch P, Ryan R et al. ( 2015 ) . P0792 : Baseline factors associated with increased SVR rates in 123 treatment-naïve chronic HCV genotype 1 patients treated with a shortened 12-week simeprevir plus pegylated interferon and ribavirin regimen: a multivariate analysis . Journal of Hepatology . vol. 62 , s629 - s630 .

Wedemeyer H, Berg T, Flamm SL, Foster GR, Craxi A, Larrey D, Morgan TR, Fried MW et al. ( 2015 ) . P0808 : Improvement in liver function and non-invasive estimates of liver fibrosis 48 weeks after treatment with ombitasvir/paritaprevir/R, dasabuvir and ribavirin in HCV genotype 1 patients with cirrhosis . Journal of Hepatology . vol. 62 , s637 - s638 .

Grebely J, Dalgard O, Conway B, Foster G, Bruggmann P, Backmund M, Robaeys G, Swan T et al. ( 2015 ) . P0848 : Efficacy of response-guided pegylated interferon and ribavirin therapy for people who inject drugs with HCV genotype 2/3 infection: The activate study . Journal of Hepatology . vol. 62 ,

Hassanein T, Roberts S, Shafran SD, Makara M, Bennett M, Müllhaupt B, Poordad F, Ryder S et al. ( 2015 ) . P0908 : Adherence to ombitasvir/paritaprevir/r, dasabuvir, and ribavirin is >98% in the Sapphire-I and Sapphire-II trials . Journal of Hepatology . vol. 62 ,

Orkin C, Leach E, Flanagan S, Wallis E, Foster GR, Ruf M, Tong CY ( 2015 ) . P1247 : Unexpected high prevalence of HCV-viraemia (HCVRNA+) in the emergency department (ED) of a London hospital - should we be screening for HCV in ED attendees? . Journal of Hepatology . vol. 62 ,

Mathew S, Petrova M, Hendy J, de Lusignan S, Zamani J, Tiwari R, Nicholls M, Kennedy P et al. ( 2015 ) . P1260 : Perceptions of viral hepatitis testing in migrant communities and the primary care physicians that serve them . Journal of Hepatology . vol. 62 ,

Hickman M, Martin N, Vickerman P, David G, Hutchinson S, Martin T, Dore G, Grebeley J et al. ( 2015 ) . P1271 : How should scale up of HCV antiviral treatment be prioritized? A cost-effectiveness analysis including individual and population prevention benefits . Journal of Hepatology vol. 62 ,

Kunkel J, Sweeney L, Falla A, Veldhuijzen I, Foster GR ( 2015 ) . P1277 : Screening for viral hepatitis among migrants in the EU: What lessons can we learn from poor response to a pilot trial using GP registers? . Journal of Hepatology . vol. 62 ,

Asselah T, Charlton M, Feld J, Foster GR, Mcnally J, Brainard DM, McHutchison JG, Mangia A et al. ( 2015 ) . P1332 : The astral studies: evaluation of SOF/GS-5816 single tablet regimen for the treatment of genotype 1–6 HCV infection . Journal of Hepatology . vol. 62 , s855 - s856 .

Sweeney L, Owiti JA, Beharry A, Bhui K, Gomes J, Foster GR, Greenhalgh T ( 2015 ) . Informing the design of a national screening and treatment programme for chronic viral hepatitis in primary care: qualitative study of at-risk immigrant communities and healthcare professionals . BMC Health Services Research vol. 15 , ( 1 )

Foster GR, Gore C, Hudson M, Moss P, Ustianowski A, Ryder S, Bhagani S ( 2015 ) . Response from Hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widespread screening for hepatitis C is justified . The BMJ vol. 350 , ( feb24 10 )

Owiti JA, Greenhalgh T, Sweeney L, Foster GR, Bhui KS ( 2015 ) . Illness perceptions and explanatory models of viral hepatitis B & C among immigrants and refugees: a narrative systematic review . BMC public health vol. 15 ,

ORKIN C, LEACH E, FLANAGAN S, WALLIS E, RUF M, FOSTER GR, TONG CYW ( 2015 ) . High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: should we be screening for HCV in ED attendees? . Epidemiology and Infection vol. 143 , ( 13 ) 2837 - 2840 .

Gill US, Zissimopoulos A, Al-Shamma S, Burke K, McPhail MJW, Barr DA, Kallis YN, Marley RTC et al. ( 2015 ) . Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? . J Infect Dis vol. 211 , ( 3 ) 374 - 382 .

Foster GR ( 2015 ) . Mutant Ninja viruses . Hepatology vol. 61 , ( 2 ) 421 - 423 .

Feld JJ, Jacobson IM, Jensen DM, Foster GR, Pol S, Tam E, Jablkowski M, Berak H et al. ( 2015 ) . Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin . J Hepatol vol. 62 , ( 2 ) 294 - 302 .

Foster GR ( 2015 ) . Shorter treatments for hepatitis C: another step forward? . The Lancet vol. 385 , ( 9973 ) 1054 - 1055 .

Ferenci P, Asselah T, Foster GR, Zeuzem S, Sarrazin C, Moreno C, Ouzan D, Maevskaya M et al. ( 2015 ) . STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection . Journal of Hepatology vol. 62 , ( 6 ) 1246 - 1255 .

Gill US, Rivino L, Le Bert N, Kunasegaran K, Tan D, Koh S, Van den Berg M, Cheng Y et al. ( 2015 ) . Characterisation of the immune profile in Chronic Hepatitis B, with CyTOF, to identify biomarkers of immune control following NUC therapy discontinuation . HEPATOLOGY . vol. 62 , 294A - 294A .

Chan HL-Y, Ahn SH, Chuang W-L, Tabak F, Mehta R, Petersen J, Wu G, Martins EB et al. ( 2015 ) . Early Decline in Serum HBsAg at Week 4 and 12 of Therapy with Tenofovir Disoproxil Fumarate and Pegylated Interferon is Predictive of HBsAg Loss . HEPATOLOGY . vol. 62 , 1190A - 1190A .

Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster G, Craxi A, Buggisch P, Sanai F et al. ( 2015 ) . Efficacy and safety of a 12-week simeprevir plus peginterferon/ribavirin regimen in treatment-naive HCV genotype 4-infected patients with mild-to-moderate fibrosis . JOURNAL OF VIRAL HEPATITIS vol. 22 , 25 - 25 .

Verma S, Foster GR, Irving W, McLauchlan J, Cheung MC, Hudson BE, Carey I, Agarwal K ( 2015 ) . Health resource usage in peri-transplant patients during 12 weeks of therapy with sofosbuvir (SOF), with or without ribavirin (RBV) and an NS5A inhibitor . HEPATOLOGY . vol. 62 , 789A - 790A .

Shafran S, Shaw D, Cohen E, Agarwal K, Foster GR, Abunimeh M, Cohen DE, Gane EJ ( 2015 ) . High Rates of SVR in Patients with HCV Genotype 2 or 3 Infection Treated with Ombitasvir/Paritaprevir/r and Sofosbuvir with or without Ribavirin . HEPATOLOGY vol. 62 , ( 6 ) 1390A - 1390A .

Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxi A, Buggisch P, Sanai FM et al. ( 2015 ) . High efficacy of a 12-week simeprevir plus peginterferon alfa 2a/ribavirin regimen in treatment-naive patients with chronic HCV genotype 4 infection and mild-to-moderate fibrosis . HEPATOLOGY . vol. 62 , 792A - 793A .

Gill US, Peppa D, Micco L, Singh HD, Carey I, Foster GR, Maini MK, Kennedy PT ( 2015 ) . NK cell function is restored with sequential NUC therapy and correlates with treatment response in Chronic Hepatitis B . HEPATOLOGY . vol. 62 , 1001A - 1002A .

Gane EJ, Pianko S, Roberts SK, Thompson AJ, Zeuzem S, Zuckerman E, Ben Ari Z, Foster GR et al. ( 2015 ) . Phase 2, Randomized, Open-Label Clinical Trials of the Efficacy and Safety of Grazoprevir and MK-3682 (NS5B Polymerase Inhibitor) with Either Elbasvir or MK-8408 (NS5A Inhibitor) in Patients with Chronic HCV GT1, 2 or 3 Infection (Part A of C-CREST-1 & 2) . HEPATOLOGY vol. 62 , ( 6 ) 1389A - 1389A .

Strasser S, Chan H, Ahn S, Chuang W, Hui A, Tabak F, Mehta R, Petersen J et al. ( 2015 ) . Predictors of clinical response: results from a large, randomized controlled study with Tenofovir Disoproxil Fumarate (TDF) plus Peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB) . JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY vol. 30 , 91 - 92 .

Hansi NK, Seipt CC, Gill US, Naik S, Tong W, Foster GR, Carey I, Kennedy PT ( 2015 ) . Quantitative Hepatitis B surface antigen (qHBsAg) may define low-risk inactive carriers of CHB: Can this provide a framework for better management across all age-groups? . HEPATOLOGY . vol. 62 , 976A - 977A .

Verma S, Carey I, Childs KE, Ayers A, Morgan P, Considine AB, Oakes K, Heneghan MA et al. ( 2015 ) . Ribavirin levels at treatment weeks (TW) 4-6 can predict sustained viriological response (SVR12) in HCV cirrhotic patients treated with all oral direct-acting antiviral therapy (DAAs) . HEPATOLOGY . vol. 62 , 750A - 750A .

Pianko S, Cooper C, Brown A, Forton D, Nahass R, George J, Barnes E, Brainard D et al. ( 2015 ) . Sofosbuvir plus Peginterferon/Ribavirin for 12 weeks vs. Sofosbuvir plus Ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON study . JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY vol. 30 , 90 - 90 .

Mangia A, Roberts SK, Pianko S, Thompson AJ, Cooper C, Conway B, Bourliere M, Asselah T et al. ( 2015 ) . Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV Infected Patients: The Randomized Controlled Phase 3 ASTRAL-3 Study . HEPATOLOGY . vol. 62 , 338A - 339A .

Zeuzem S, Gane E, Agarwal K, Cohen D, Xie W, Dylla D, Tatsch F, Foster G ( 2015 ) . Sustained virologic response rates in HCV genotype 1-infected patients treated for 8 weeks with ombitasvir/paritaprevir/r and dasabuvir with ribavirin . JOURNAL OF VIRAL HEPATITIS vol. 22 , 27 - 27 .

Lahiri R, Derwa Y, Bashir Z, Giles E, Torrance HD, Owen HC, O'Dwyer MJ, O'Brien A et al. ( 2015 ) . Systemic Inflammatory Response Syndrome After Major Abdominal Surgery Predicted by Early Upregulation of TLR4 and TLR5 . Annals of Surgery vol. 263 , ( 5 ) 1028 - 1037 .

Marcellin P, Wursthorn K, Wedemeyer H, Chuang W-L, Lau G, Avila C, Peng C-Y, Gane E et al. ( 2015 ) . Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy . J Hepatol vol. 62 , ( 1 ) 41 - 47 .

Chan HL-Y, Ahn SH, Chuang W-L, Tabak F, Mehta R, Petersen J, Kim K, Dinh P et al. ( 2015 ) . Treatment and HBeAg-status Differentiate Clinical Outcomes Following ALT Flares - Analysis of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon (PEG) Combination Study for Chronic Hepatitis B (CHB) . HEPATOLOGY . vol. 62 , 333A - 334A .

Foster G ( 2015 ) . Which DAA regime should include ribavirin? . JOURNAL OF VIRAL HEPATITIS vol. 22 , 2 - 3 .

Foster G, Afdhal NH, Karayiannis P, Thursz M ( 2014 ) . Welcome to the new, all electronic Journal of Viral Hepatitis . Journal of Viral Hepatitis vol. 22 , ( 1 ) 1 - 1 .

Petersen J ( 2014 ) . Do we need more nucleos(t)ide analogs for the treatment of chronic hepatitis B? . Journal of Hepatology vol. 62 , ( 3 ) 505 - 507 .

Feld JJ, Weiland O, Marinho RT, Wedemeyer H, Jacobson IM, Jensen DM, Hassanein T, De Ledinghen V et al. ( 2014 ) . 1222ABT-450/r/Ombitasvir and Dasabuvir with Ribavirin Achieves High Sustained Virologic Response Rates Regardless of Baseline Characteristics: Pooled Analyses of the SAPPHIRE-I and SAPPHIRE-II Studies . Open Forum Infectious Diseases vol. 1 , ( suppl_1 ) s41 - s42 .

Foster GR, De Silva S ( 2014 ) . Hepatitis C genotype 1 . Curr Opin Infect Dis vol. 27 , ( 6 ) 535 - 539 .

Berg T, Andreone P, Pol S, Roberts S, Younossi Z, Diago M, Lawitz EJ, Focaccia R et al. ( 2014 ) . Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study . Liver International vol. 35 , ( 2 ) 448 - 454 .

Potter J, Hyams C, Shaukat M, Babiker Z, Macavei V, Jayasekera N, Kunst H, Foster G et al. ( 2014 ) . P189 Should Screening For Chronic Viral Hepatitis In Patients With Tuberculosis Be Introduced To Nice Guidelines? . Thorax . vol. 69 , a159 - a159 .

Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A, Ferguson J, Forton D et al. ( 2014 ) . Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis . The Lancet vol. 384 , ( 9958 ) 1953 - 1997 .

Alazawi W, Mathur R, Abeysekera K, Hull S, Boomla K, Robson J, Foster GR ( 2014 ) . Ethnicity and the diagnosis gap in liver disease: a population-based study . Br J Gen Pract vol. 64 , ( 628 ) e694 - e702 .

Buti M, Foster GR, Asselah T ( 2014 ) . Hepatitis C triple therapy in the near future: New opportunities to cure . Journal of Hepatology vol. 61 , ( 5 )

Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, Flaherty JF, Lawson E et al. ( 2014 ) . Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection . Journal of Hepatology vol. 62 , ( 3 ) 533 - 540 .

Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, Dillon JF, Craine N et al. ( 2014 ) . HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact . Journal of Viral Hepatitis vol. 22 , ( 4 ) 399 - 408 .

Chan CHH, Pieper IL, Fleming S, Friedmann Y, Foster G, Hawkins K, Thornton CA, Kanamarlapudi V ( 2014 ) . The Effect of Shear Stress on the Size, Structure, and Function of Human von Willebrand Factor . Artificial Organs vol. 38 , ( 9 ) 741 - 750 .

Head MG, Fitchett JR, Cooke GS, Foster GR, Atun R ( 2014 ) . Systematic analysis of funding awarded for viral hepatitis‐related research to institutions in the United Kingdom, 1997–2010 . Journal of Viral Hepatitis vol. 22 , ( 3 ) 230 - 237 .

Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A et al. ( 2014 ) . Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial . Lancet vol. 384 , ( 9941 ) 403 - 413 .

Chan CHH, Pieper IL, Hambly R, Radley G, Jones A, Friedmann Y, Hawkins KM, Westaby S et al. ( 2014 ) . The CentriMag Centrifugal Blood Pump as a Benchmark for In Vitro Testing of Hemocompatibility in Implantable Ventricular Assist Devices . Artificial Organs vol. 39 , ( 2 ) 93 - 101 .

Foster G ( 2014 ) . Journal of Viral Hepatitis commencing January 2015 . Journal of Viral Hepatitis vol. 21 , ( 7 ) 457 - 457 .

Appleby V, Khan A, Rehman J, Foster G, Moreea S ( 2014 ) . PTH-091 Testing For Hepatitis C In High Risk Immigrants – Findings From A Single Practice With A Large Immigrant Population . Gut vol. 63 , ( Suppl 1 )

Appleby V, Khan A, Rehman J, Foster G, Moreea S ( 2014 ) . PWE-158 Screening Immigrants Originating From High Prevalence Areas For Hepatitis B Using Primary Care Databases – Experience From A Single Gp Practice With A Large Migrant Population . Gut vol. 63 , ( Suppl 1 )

Alazawi W, Mathur R, Abeysekera K, Hull S, Boomla K, Robson J, Foster G ( 2014 ) . PTU-138 Population-based Study Of Ethnicity And The Diagnosis Gap In Liver Disease . Gut vol. 63 Suppl 1 ,

Shoeb D, Dearden J, Weatherall A, Bargery C, Moreea S, Alam S, White E, Vila X et al. ( 2014 ) . Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial . J Hepatol vol. 60 , ( 4 ) 699 - 705 .

Mangia A, Marcellin P, Kwo P, Foster GR, Buti M, Bräu N, Muir A, Yang JC et al. ( 2014 ) . O164 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-1 STUDY . Journal of Hepatology . vol. 60 , s523 - s524 .

Foster GR, Strasser S, Christensen C, Ma J, Bekele BN, Brainard DM, Symonds WT, McHutchison JG et al. ( 2014 ) . O66 SOFOSBUVIR-BASED REGIMENS ARE ASSOCIATED WITH HIGH SVR RATES ACROSS GENOTYPES AND AMONG PATIENTS WITH MULTIPLE NEGATIVE PREDICTIVE FACTORS . Journal of Hepatology . vol. 60 ,

Foster GR, Coppola C, Curescu M, Derbala M, Esmat G, Ferenci P, Flisiak R, Lengyel G et al. ( 2014 ) . P1126 IMPACT OF SAFETY-RELATED DOSE REDUCTIONS AND DISCONTINUATIONS (SR-RD) ON SUSTAINED VIROLOGICAL RESPONSE (SVR) IN TREATMENT-NAIVE CHRONIC HEPATITIS C PATIENTS RECEIVING PEGINTERFERON ALFA-2a/RIBAVIRIN: RESULTS FROM GUARD-C . Journal of Hepatology . vol. 60 ,

Mangia A, De Ledinghen V, Bailly F, Brahm J, Keiss J, Valantinas J, Rasmann N, Riachi G et al. ( 2014 ) . P1167 rs12979860 IL28B GENOTYPE IS ASSOCIATED WITH ADVANCED FIBROSIS IN HCV GENOTYPE 1-INFECTED EUROPEAN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS FROM THE INTERNATIONAL GEN-C STUDY . Journal of Hepatology . vol. 60 ,

Martin NK, Devine A, Eaton JW, Hallett TB, Foster GR, Dore GJ, Easterbrook PJ, Legood R et al. ( 2014 ) . P1190 MODELING THE IMPACT OF EARLY ANTIRETROVIRAL THERAPY FOR ADULTS COINFECTED WITH HIV AND HEPATITIS B OR C IN SOUTH AFRICA . Journal of Hepatology . vol. 60 ,

Sweeney L, Greenhalgh T, Owiti J, Bhui K, Gomes J, Foster G ( 2014 ) . P1275 UNDERSTANDING OF HEPATITIS B AND C: A QUALITATIVE STUDY WITH IMMIGRANT COMMUNITIES AT INCREASED RISK OF CHRONIC INFECTION . Journal of Hepatology . vol. 60 ,

Lewis H, Kunkel J, Wilkinson M, Foster GR ( 2014 ) . P1297 A NOVEL NURSE LED MODEL OF TREATMENT DOES NOT INCREASE TREATMENT RATES IN INJECTION DRUG USERS WITH HEPATITIS C VIRUS . Journal of Hepatology . vol. 60 ,

Gill US, Peppa D, Micco L, Singh HD, Foster GR, Maini MK, Kennedy PTF ( 2014 ) . P152 SEQUENTIAL NUC THERAPY FOLLOWING PEGYLATED INTERFERON-ALPHA EXPOSURE RESTORES INNATE IMMUNE RESPONSES CONFERRING A TREATMENT ADVANTAGE OVER NUC MONOTHERAPY IN CHRONIC HEPATITIS B . Journal of Hepatology . vol. 60 ,

Umar M, Khan AG, Abbas Z, Arora S, Asifabbas N, Elewaut A, Esmat G, Foster G et al. ( 2014 ) . World Gastroenterology Organisation Global Guidelines . Journal of Clinical Gastroenterology vol. 48 , ( 3 ) 204 - 217 .

Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hezode C, Hirschfield GM et al. ( 2014 ) . Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial . Gastroenterology vol. 146 , ( 2 ) 430 - 41.e6 .

Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo P et al. ( 2014 ) . Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1 . N Engl J Med vol. 370 , ( 3 ) 222 - 232 .

Foster G, Karayiannis P, Afdhal N ( 2014 ) . Editorial . Journal of Viral Hepatitis vol. 21 , ( 2 ) 77 - 77 .

Puoti M, Cooper C, Sulkowski MS, Foster GR, Berg T, Villa E, Rodriguez-Perez F, Rustgi V et al. ( 2014 ) . ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of Efficacy and Safety in Phase 2 and Phase 3 Trials . HEPATOLOGY . vol. 60 , 1135A - 1136A .

Gill US, Peppa D, Singh HD, Micco L, Foster GR, Maini MK, Kennedy PT ( 2014 ) . Functional innate immune responses are restored with sequential NUC therapy following Pegylated Interferon-Alpha exposure and not with NUC monotherapy in Chronic Hepatitis B . HEPATOLOGY . vol. 60 , 1020A - 1021A .

Foster GR, De Silva S ( 2014 ) . Hepatitis C genotype 1 . Current Opinion in Infectious Diseases vol. 27 , ( 6 ) 535 - 539 .

Foster G, Strasser S, Christensen C, Ma J, Bekele N, Brainard D, Mchutchison J, Chan A et al. ( 2014 ) . High SVR rates among patients with multiple negative predictive factors across genotypes treated with sofosbuvir-based regimens . JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY vol. 29 , 194 - 194 .

Hansi NK, Gill US, Banerjee A, Surendraraj N, Patel C, Naik S, Foster GR, Kennedy PT ( 2014 ) . High levels of Hepatitis B surface antigen (HBsAg) can exclude significant fibrosis and distinguishes true 'immune-tolerance' in children and young adults with Chronic Hepatitis B . HEPATOLOGY . vol. 60 , 985A - 986A .

Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski J-P et al. ( 2014 ) . Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection . NEW ENGLAND JOURNAL OF MEDICINE vol. 370 , ( 20 ) 1889 - 1898 .

Martin NK, Devine A, Eaton JW, Miners A, Hallett TB, Foster GR, Dore GJ, Easterbrook PJ et al. ( 2014 ) . Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa . AIDS vol. 28 Suppl 1 , S35 - S46 .

Zeuzem S, Demasi R, Foster GR, Buti M, Baldini A, Luo D, Witek J, Rizzetto M ( 2014 ) . PREDICTION OF SUSTAINED VIROLOGIC RESPONSE IN TREATMENT-NAIVE CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS TREATED WITH TELAPREVIR PLUS PEGYLATED INTERFERON AND RIBAVIRIN IN PHASE 3 TRIALS . JOURNAL OF HEPATOLOGY . vol. 60 , S452 - S452 .

Miller MH, Agarwal K, Austin A, Brown A, Barclay ST, Dundas P, Dusheiko GM, Foster GR et al. ( 2014 ) . Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy . ALIMENTARY PHARMACOLOGY & THERAPEUTICS vol. 39 , ( 12 ) 1363 - 1375 .

Thompson A, Foster GR, Strasser S, Christensen C, Ma J, Bekele N, Brainard DM, Symonds WT et al. ( 2014 ) . Sofosbuvir-based regimens are associated with high SVR rates across genotypes and among patients with multiple negative predictive factors . JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY vol. 29 , 70 - 70 .

Martin NK, Vickerman P, Dore GJ, Grebely J, Foster GR, Miners A, Hutchinson S, Goldberg DJ et al. ( 2014 ) . Who should be prioritized for HCV antiviral treatment? A cost-effectiveness analysis including individual and population prevention benefits . HEPATOLOGY . vol. 60 , 1042A - 1042A .

Roberts SJ, Owen HC, Tam WL, Solie L, Van Cromphaut SJ, Van den Berghe G, Luyten FP ( 2013 ) . Humanized Culture of Periosteal Progenitors in Allogeneic Serum Enhances Osteogenic Differentiation and In Vivo Bone Formation . Stem Cells Translational Medicine vol. 3 , ( 2 ) 218 - 228 .

Younossi Z, Negro F, Serfaty L, Pol S, Diago M, Zeuzem S, Andreone P, Lawitz EJ et al. ( 2013 ) . Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial . Hepatology vol. 58 , ( 6 ) 1897 - 1906 .

Foster G ( 2013 ) . KL1: SWOT analysis of currently available anti‐HCV therapies . Journal of Viral Hepatitis vol. 20 , ( s3 ) 1 - 1 .

Chan CHH, Hilton A, Foster G, Hawkins KM, Badiei N, Thornton CA ( 2013 ) . The Evaluation of Leukocytes in Response to the In Vitro Testing of Ventricular Assist Devices . Artificial Organs vol. 37 , ( 9 ) 793 - 801 .

Sali S, Alavian SM, Foster GR, Keyvani H, Mehrnoosh L, Mohammadi N ( 2013 ) . Influencing Factors on the Outcome and Prognosis of Patients With HBV Infction: Seven Years Follow-up . Hepatitis Monthly vol. 13 , ( 7 )

Kunkel J, Wilkinson M, Foster GR ( 2013 ) . PTH-149 Successful Care for Patients with Chronic Hepatitis B Virus Infection in a Dedicated Drug and Alcohol Addiction Service in East London . Gut vol. 62 , ( Suppl 1 )

Lahiri RP, Abeles A, Burnand KM, Alazawi W, Bhattacharya S, Foster GR, Knowles CH ( 2013 ) . A cross sectional study of colonic diverticulosis in the London Bangladeshi population . United European Gastroenterol J vol. 1 , ( 3 ) 191 - 197 .

Foster GR ( 2013 ) . Reply to: "usefulness of Lead-In phase in determining risk/benefit of telaprevir treatment in patients with HCV cirrhosis" . J Hepatol vol. 58 , ( 6 )

Alazawi W, Heath H, Waters JA, Woodfin A, O'Brien AJ, Scarzello AJ, Ma B, Lopez-Otalora Y et al. ( 2013 ) . Stat2 loss leads to cytokine-independent, cell-mediated lethality in LPS-induced sepsis . Proc Natl Acad Sci U S A vol. 110 , ( 21 ) 8656 - 8661 .

Lewis H, Foster G ( 2013 ) . Telaprevir: evidence and guidance for use in clinical practice . Journal of clinical practice vol. 10 , ( 3 ) 265 - 273 .

Alazawi W, Lahiri R, Spyrou A, Giles E, Bashir Z, O'Brien A, Stagg A, Waters J et al. ( 2013 ) . 319 PATIENTS WITH COMPENSATED CIRRHOSIS HAVE SELECTIVE PARESIS OF FLAGELLIN-INDUCED INNATE IMMUNE RESPONSES DUE TO FAILURES IN ERK SIGNALLING . Journal of Hepatology . vol. 58 , s133 - s134 .

Foster GR, Zeuzem S, Pianko S, Sarin SK, Piratvisuth T, Shah S, Andreone P, Sood A et al. ( 2013 ) . Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin . Journal of Viral Hepatitis vol. 20 , ( 4 )

Carswell D, McBride D, Croft TN, Slone AK, Cross M, Foster G ( 2013 ) . A CFD model for the prediction of haemolysis in micro axial left ventricular assist devices . Applied Mathematical Modelling vol. 37 , ( 6 ) 4199 - 4207 .

Foster GR, Zeuzem S, Andreone P, Pol S, Lawitz EJ, Diago M, Roberts S, Pockros PJ et al. ( 2013 ) . Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure . J Hepatol vol. 58 , ( 3 ) 488 - 494 .

Couper S, Bird SM, Foster GR, McMenamin J ( 2013 ) . Opportunities for protecting prisoner health: Influenza vaccination as a case study . Public Health vol. 127 , ( 3 ) 295 - 296 .

Carswell D, Hilton A, Chan C, McBride D, Croft N, Slone A, Cross M, Foster G ( 2013 ) . Development of a radial ventricular assist device using numerical predictions and experimental haemolysis . Medical Engineering & Physics vol. 35 , ( 8 ) 1197 - 1203 .

Pol S, Aerssens J, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, Younossi Z, Foster GR et al. ( 2013 ) . Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure . Journal of Hepatology vol. 58 , ( 5 ) 883 - 889 .

Martin NK, Vickerman P, Clements A, Cramp M, De Angeles D, Dillon JF, Fahey S, Foster GR et al. ( 2013 ) . ARE CURRENT TREATMENT RATES SUFFICIENT TO REDUCE HCV PREVALENCE AMONG PEOPLE WHO INJECT DRUGS? MODEL PROJECTIONS IN SEVEN UK SETTINGS . JOURNAL OF HEPATOLOGY . vol. 58 , S356 - S356 .

De Meyer S, Ghys A, Foster GR, Beumont M, Van Baelen B, Lin T-I, Dierynck I, Ceulemans H et al. ( 2013 ) . Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes . JOURNAL OF VIRAL HEPATITIS vol. 20 , ( 6 ) 395 - 403 .

Burger D, Back D, Buggisch P, Buti M, Craxi A, Foster G, Klinker H, Larrey D et al. ( 2013 ) . Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions . JOURNAL OF HEPATOLOGY vol. 58 , ( 4 ) 792 - 800 .

Gill US, Patel C, Naik S, Dearden J, Kallis YN, Kooner P, Marley R, Aleong J-AC et al. ( 2013 ) . Collagen proportionate area but not Ishak fibrosis stage on liver biopsy correlates with age in Chronic Hepatitis B infected young adults . HEPATOLOGY . vol. 58 , 427A - 428A .

Foster GR, Zeuzem S, Pianko S, Sarin SK, Piratvisuth T, Shah S, Andreone P, Sood A et al. ( 2013 ) . Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin . Journal of Viral Hepatitis

Chen A, Gill US, Ikin CR, Aleong J-AC, Foster GR, Kennedy PT ( 2013 ) . Differential Hepatitis B virus core nuclear/cytoplasmic staining is a marker of longevity of chronic infection but not disease phase . HEPATOLOGY . vol. 58 , 423A - 424A .

Gill US, Zissimopoulos A, Al-shamma S, Burke K, McPhail M, Barr D, Ross V, Kallis Y et al. ( 2013 ) . FRAX SCORE IN THE ASSESSMENT OF BONE MINERAL DENSITY CHANGES IN TENOFOVIR TREATED CHRONIC HEPATITIS B PATIENTS . GUT . vol. 62 , A190 - A190 .

Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster GR, Dillon JF et al. ( 2013 ) . Hepatitis C Virus Treatment for Prevention Among People Who Inject Drugs: Modeling Treatment Scale-Up in the Age of Direct-Acting Antivirals . HEPATOLOGY vol. 58 , ( 5 ) 1598 - 1609 .

Alazawi W, Abeysekera K, Dearden J, Glynn M, Kallis Y, Kennedy P, Marley R, Foster GR et al. ( 2013 ) . IMPLEMENTING EASL & AASLD GUIDELINES FOR HEPATOCELLULAR CARCINOMA SCREENING IS COST-EFFECTIVE IN LONDON'S ETHNICALLY DIVERSE POPULATION . JOURNAL OF HEPATOLOGY . vol. 58 , S397 - S397 .

Gill US, Payaniandy L, Payaniandy D, Schulz J, Ross VA, Kallis YN, Kooner P, Marley RTC et al. ( 2013 ) . INDUCTION MAINTENANCE THERAPY IN CHRONIC HEPATITIS B; STEP-DOWN FROM COMBINATION LAMIVUDINE AND TENOFOVIR TO LAMIVUDINE MONOTHERAPY - A POTENTIAL NEW TREATMENT STRATEGY . JOURNAL OF HEPATOLOGY . vol. 58 , S302 - S302 .

Lahiri R, Wong J, Waters J, Bhattacharya S, Foster G, Alazawi W ( 2013 ) . Increased expression of toll-like receptor (TLR) 4 and TLR5 following complex hepato-pancreatico-biliary (HPB) surgery predicts the development of post-operative systemic inflammatory response syndrome (SIRS) . BRITISH JOURNAL OF SURGERY . vol. 100 , 20 - 21 .

Alazawi W, Abeysekera K, Boomla K, Foster GR ( 2013 ) . POPULATION BASED STUDY OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) SHOWS DISEASE IS MORE COMMON AMONG BANGLADESHIS IN ETHNICALLY DIVERSE BOROUGHS OF LONDON . JOURNAL OF HEPATOLOGY . vol. 58 , S530 - S530 .

Foster G, Shoeb D, Weatherall A, Moreea S, Vilar J, Freshwater D, Ryder S, Alexander G et al. ( 2013 ) . RANDOMISED CONTROLLED TRIAL OF 24 AND 48 WEEKS OF PEGYLATED INTERFERON alfa 2a PLUS RIBAVIRIN IN PATIENTS WITH GENOTYPE 3 HCV AND CIRRHOSIS . JOURNAL OF HEPATOLOGY . vol. 58 , S335 - S335 .

Marcellin P, Xie Q, Piratvisuth T, Foster GR, Flisiak R, Chen XY, Xie Y, Chen YP et al. ( 2013 ) . S-Collate COHORT 'REAL-LIFE' STUDY: EFFICACY AND SAFETY OF PEGINTERFERON alfa-2a (40KD) IN 1233 PATIENTS WITH CHRONIC HEPATITIS B ACCORDING TO ASIAN AND CAUCASIAN RACE . JOURNAL OF HEPATOLOGY . vol. 58 , S18 - S18 .

Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson D, Zeuzem S, Everson GT, Kwo P et al. ( 2013 ) . SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333+/- RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY . JOURNAL OF HEPATOLOGY . vol. 58 , S2 - S2 .

Kunkel J, Ahmad A, Levi M, Reintjes R, Veldhuijzen I, Foster G ( 2013 ) . SCREENING FOR VIRAL HEPATITIS AMONG MIGRANTS IN THE EU - THE QUEST FOR 'GOOD SCREENING PRACTICE' . JOURNAL OF HEPATOLOGY . vol. 58 , S400 - S401 .

Gill US, Payaniandy L, Schulz J, Payaniandy D, Ross V, Kallis Y, Kooner P, Marley R et al. ( 2013 ) . SEQUENTIAL ORAL ANTI-VIRAL THERAPY FOLLOWING PEGYLATED-INTERFERON-ALPHA FAILURE SIGNIFICANTLY INCREASES HBSAG DECLINE . GUT . vol. 62 , A189 - A190 .

Jacobson I, Dore GJ, Foster GR, Fried MW, Radu M, Rafalskiy VV, Moroz L, Craxi A et al. ( 2013 ) . SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAIVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL . JOURNAL OF HEPATOLOGY . vol. 58 , S574 - S574 .

Kowdley K, Lawitz E, Poordad F, Cohen D, Nelson D, Zeuzem S, Everson G, Kwo P et al. ( 2013 ) . Safety and Efficacy of Interferon-free Regimens of ABT-450/r, ABT-267, ABT-333 ± Ribavirin in Patients with Chronic HCV GTI Infection: Results from the Aviator Study . AMERICAN JOURNAL OF GASTROENTEROLOGY . vol. 108 , S108 - S108 .

Gill US, Peppa D, Micco L, Foster GR, Maini MK, Kennedy PT ( 2013 ) . Sustained restoration of innate immune responses and sAg decline in sequential NUC therapy following failed Pegylated-Interferon-α therapy in Chronic Hepatitis B . HEPATOLOGY . vol. 58 , 416A - 417A .

Zeuzem S, DeMasi R, Foster GR, Buti M, Laeuffer JM, Luo D, Witek J, Rizzetto M ( 2013 ) . Telaprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with genotype 1 HCV and mild to moderate liver disease . HEPATOLOGY . vol. 58 , 1129A - 1129A .

Lahiri R, Abeles A, Burnand K, Alazawi W, Foster G, Knowles C ( 2013 ) . The London Bangladeshi community: A population protected against the disease of western civilisation . BRITISH JOURNAL OF SURGERY . vol. 100 , 40 - 40 .

O'Leary MC, Sarwar M, Hutchinson SJ, Weir A, Schofield J, McLeod A, Cameron S, McTaggart C et al. ( 2013 ) . The prevalence of hepatitis C virus among people of South Asian origin in Glasgow - Results from a community based survey and laboratory surveillance . TRAVEL MEDICINE AND INFECTIOUS DISEASE vol. 11 , ( 5 ) 301 - 309 .

Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, Flaherty JF, Lawson E et al. ( 2013 ) . Twenty Eight Day Safety and Efficacy of Tenofovir Alafenamide (TAF) Fumarate in Chronic Hepatitis B (CHB) Patients . HEPATOLOGY . vol. 58 , 675A - 675A .

George PM, Cunningham ME, Galloway-Phillipps N, Badiger R, Alazawi W, Foster GR, Mitchell JA ( 2012 ) . Endothelin-1 as a mediator and potential biomarker for interferon induced pulmonary toxicity . Pulm Circ vol. 2 , ( 4 ) 501 - 504 .

Kennedy PTF, Sandalova E, Jo J, Gill U, Ushiro-Lumb I, Tan AT, Naik S, Foster GR et al. ( 2012 ) . Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B . Gastroenterology vol. 143 , ( 3 ) 637 - 645 .

Chan CHH, Hilton A, Foster G, Hawkins K ( 2012 ) . Reevaluation of the Harboe Assay as a Standardized Method of Assessment for the Hemolytic Performance of Ventricular Assist Devices . Artificial Organs vol. 36 , ( 8 ) 724 - 730 .

Lewis H, Cunningham M, Foster G ( 2012 ) . Second generation direct antivirals and the way to interferon-free regimens in chronic HCV . Best Pract Res Clin Gastroenterol vol. 26 , ( 4 ) 471 - 485 .

Foster G, Yeo W, Ramsay L ( 2012 ) . Effect of sulindac on the cough reflex of healthy subjects . British Journal of Clinical Pharmacology vol. 31 , ( 2 ) 207 - 208 .

Yeo W, Higgins K, Foster G, Jackson P, Ramsay L ( 2012 ) . Effect of dose adjustment on enalapril‐induced cough and the response to inhaled capsaicin . British Journal of Clinical Pharmacology vol. 39 , ( 3 ) 271 - 276 .

Khan R, Foster GR, Chowdhury TA ( 2012 ) . Managing diabetes in patients with chronic liver disease . Postgrad Med vol. 124 , ( 4 ) 130 - 137 .

George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA ( 2012 ) . Pharmacology and therapeutic potential of interferons . Pharmacol Ther vol. 135 , ( 1 ) 44 - 53 .

Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J, Rosenberg WM ( 2012 ) . Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis . Eur J Gastroenterol Hepatol vol. 24 , ( 5 ) 543 - 550 .

Harris RJ, Ramsay M, Hope VD, Brant L, Hickman M, Foster GR, De Angelis D ( 2012 ) . Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis . Eur J Public Health vol. 22 , ( 2 ) 187 - 192 .

Cunningham M, Foster GR ( 2012 ) . Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection . Therap Adv Gastroenterol vol. 5 , ( 2 ) 139 - 151 .

Humphreys IS, von Delft A, Brown A, Hibbert L, Collier JD, Foster GR, Rahman M, Christian A et al. ( 2012 ) . HCV genotype-3a T cell immunity: specificity, function and impact of therapy . Gut vol. 61 , ( 11 )

Foster GR, Serfaty LD ( 2012 ) . Triple combination treatment for chronic hepatitis C with protease inhibitors, pegylated interferon and ribavirin: 'lead-in or no lead-in'? . Liver Int vol. 32 Suppl 1 , 61 - 63 .

Cunningham M, Foster GR ( 2012 ) . What to do about Hepatitis B and Hepatitis C in Patients with IBD . Clinical Dilemmas in Inflammatory Bowel Disease , Wiley

Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo PY et al. ( 2012 ) . A 12-Week Interferon-free Treatment Regimen with ABT-450/r, ABT-267, ABT-333 and Ribavirin Achieves SVR12 Rates (Observed Data) of 99% in Treatment-Naive Patients and 93% in Prior Null Responders with HCV Genotype1 Infection . HEPATOLOGY vol. 56 , ( 6 ) 1515 - 1516 .

Readhead S, Ahmed A, Jenkins H, Nicholls M, Berry P, Shafi S, Foster GR, Ala A ( 2012 ) . A prospective pilot study of the utility of finger prick dry blood spot testing (DBS) in mosques - a model for chronic viral hepatitis related community screening, health promotion and accessing health care in the UK Pakistani population . HEPATOLOGY . vol. 56 , 1095A - 1096A .

Lewis H, Igbe R, Wilkinson M, Dalton J, Gardner H, Hothi J, Ibrahim N, King K et al. ( 2012 ) . ACTIVE INJECTION DRUG USER'S CAN BE SUCCESSFULLY TREATED FOR HCV AND SIGNIFICANTLY REDUCE ILLICIT DRUG USE POST TREATMENT: REAL LIFE COHORT OF 152 PATIENTS . JOURNAL OF HEPATOLOGY . vol. 56 , S446 - S446 .

Pawlotsky J-M, Sarin SK, Foster G, Peng C-Y, Rasenack J, Flisiak R, Piratvisuth T, Wedemeyer H et al. ( 2012 ) . ALISPORIVIR PLUS RIBAVIRIN IS HIGHLY EFFECTIVE AS INTERFERON-FREE OR INTERFERON-ADD-ON REGIMEN IN PREVIOUSLY UNTREATED HCV-GT2 OR GT3 PATIENTS: SVR12 RESULTS FROM VITAL-1 PHASE 2B STUDY . JOURNAL OF HEPATOLOGY . vol. 56 , S553 - S553 .

Pawlotsky J-M, Sarin SK, Foster GR, Peng C-Y, Rasenack J, Flisiak R, Piratvisuth T, Wedemeyer H et al. ( 2012 ) . Alisporivir plus Ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: Final results from VITAL-1 study . HEPATOLOGY . vol. 56 , 309A - 310A .

Konishi H, Okamoto K, Ohmori Y, Yoshino H, Ohmori H, Ashihara M, Hirata Y, Ohta A et al. ( 2012 ) . An orally available, small-molecule interferon inhibits viral replication . Sci Rep vol. 2 ,

Foster GR, Coppola C, Derbala MF, Ferenci P, Orlandini A, Tallarico L, Ahlers S, Tatsch F et al. ( 2012 ) . BASELINE PREDICTORS FOR SAFETY-RELATED DOSE REDUCTIONS OR TREATMENT DISCONTINUATIONS AMONG PEGINTERFERON ALFA-2A (40KD)/RIBAVIRIN-TREATED PATIENTS AND THEIR IMPACT ON EARLY TREATMENT RESPONSES: GUARD-C INTERIM ANALYSIS . JOURNAL OF HEPATOLOGY . vol. 56 , S437 - S438 .

Patel C, Gill U, Alazawi W, Shaw P, Alstead EM, Kallis Y, Kooner P, Marley R et al. ( 2012 ) . Benchmarking disease activity and progression in Chronic Hepatitis B infected young adults . HEPATOLOGY . vol. 56 , 362A - 362A .

Gill US, Payaniandy L, Schulz J, Ross V, Kallis Y, Kooner P, Marley R, Ushiro-Lumb I et al. ( 2012 ) . CAN A 3-MONTH "STOPPING RULE" FOR PEGYLATED-INTERFERON-α BE APPLIED TO A UK POPULATION OF CHRONIC HEPATITIS B INFECTED PATIENTS OF MIXED GENOTYPE? . GUT vol. 61 , A145 - A145 .

Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M ( 2012 ) . Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations . HEPATOLOGY vol. 55 , ( 1 ) 49 - 57 .

Cunningham ME, Javaid A, Waters JA, Wright JD, Wong JL, McLauchlan J, Foster GR ( 2012 ) . Development and validation of a novel capture-fusion model to study primary HCV replication and anti-viral drug sensitivity . HEPATOLOGY . vol. 56 , 710A - 710A .

Cunningham ME, Schulz J, Payaniandy L, Kallis Y, Kennedy P, Kooner P, Marley R, Foster GR ( 2012 ) . EARLY EXPERIENCE WITH TELAPREVIR FOR PATIENTS WITH ADVANCED FIBROSIS OR CIRRHOSIS . GUT vol. 61 , A141 - A141 .

Patel C, Gill US, Alazawi W, Shaw P, Alstead E, Kallis Y, Kooner P, Marley R et al. ( 2012 ) . EVALUATION OF LIVER FIBROSIS IN YOUNG ADULT PATIENTS WITH CHRONIC HEPATITIS B VIRUS . GUT vol. 61 , A133 - A133 .

Lewis H, Wilkinson M, Dalton J, Gardner H, Hothi J, Ibrahim N, King K, Mirza M et al. ( 2012 ) . EXCELLENT DISEASE FREE AND OVERALL SURVIVAL RATES AFTER LONG TERM FOLLOW-UP OF A COHORT OF INJECTING DRUG USERS TREATED FOR HCV . GUT vol. 61 , A134 - A135 .

Roberts S, Pol S, Andreone P, Younossi Z, Diago M, Lawitz EJ, Focaccia R, Foster GR et al. ( 2012 ) . Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE Phase III study . JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY vol. 27 , 177 - 177 .

Alazawi W, Spyrou A, Lahiri R, Waters J, Foster GR ( 2012 ) . FLAGELLIN-INDUCED IL-6 PRODUCTION IS SELECTIVELY IMPAIRED IN PATIENTS WITH CIRRHOSIS . GUT vol. 61 , A130 - A130 .

Gill U, Zissimopoulos A, Al-Shamma S, Burke KB, Ross VA, Kallis Y, Kooner P, Marley R et al. ( 2012 ) . FRAX score in the assessment of Bone Mineral Density changes in Tenofovir treated Chronic Hepatitis B patients: comparison with bone biochemistry and DEXA scanning . HEPATOLOGY . vol. 56 , 201A - 201A .

Vergis N, Antoniades CG, Zingarelli V, Abeles RD, Ma Y, Shawcross D, Patch D, Rosenberg W et al. ( 2012 ) . FUNCTIONAL DEFECTS IN CIRCULATING MONOCYTES MAY CONTRIBUTE TO INCREASED SUSCEPTIBILTY TO INFECTION IN ALCOHOLIC HEPATITIS . JOURNAL OF HEPATOLOGY . vol. 56 , S43 - S43 .

Vergis N, Antoniades CG, Zingarelli V, Abeles RD, Ma Y, Shawcross D, Janmohamed A, Patch D et al. ( 2012 ) . FUNCTIONAL DEFECTS IN CIRCULATING MONOCYTES MAY CONTRIBUTE TO SUSCEPTIBILITY TO INFECTION IN ALCOHOLIC HEPATITIS . GUT vol. 61 , A189 - A190 .

Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, Foster GR, Kautz A et al. ( 2012 ) . Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement . JOURNAL OF HEPATOLOGY vol. 57 , ( 6 ) 1379 - 1390 .

Gill US, Payaniandy L, Payaniandy D, Schulz J, Ross V, Kallis Y, Kooner P, Marley R et al. ( 2012 ) . INDUCTION MAINTENANCE TREATMENT IN CHRONIC HEPATITIS B; STEP-DOWN FROM TENOFOVIR AND LAMIVUDINE TO LAMIVUDINE MONOTHERAPY IS EFFECTIVE . GUT vol. 61 , A145 - A145 .

Roberts S, Younossi Z, Negro F, Serfaty L, Pol S, Diago M, Zeuzem S, Andreone P et al. ( 2012 ) . Impact of insulin resistance on virologic response to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: post-hoc analysis of the REALIZE Phase III study . JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY vol. 27 , 178 - 179 .

Gill US, Papadaki M, Peppa D, Micco L, Li L, Ushiro-Lumb I, Foster GR, Maini MK et al. ( 2012 ) . MAXIMAL BOOSTING OF INNATE IMMUNITY DURING PEGYLATED INTERFERON-APLHA THERAPY IS REACHED AT 48 WEEKS IN E-ANTIGEN POSITIVE CHRONIC HEPATITIS B . JOURNAL OF HEPATOLOGY . vol. 56 , S175 - S175 .

Gill US, Papadaki M, Peppa D, Micco L, Li L, Ushiro-Lumb I, Foster GR, Maini MK et al. ( 2012 ) . MAXIMAL BOOSTING OF INNATE IMMUNITY DURING PEGYLATED INTERFERON-α THERAPY IS REACHED AT 48 WEEKS IN E-ANTIGEN POSITIVE CHRONIC HEPATITIS B . GUT vol. 61 , A145 - A146 .

Lewis H, Reynolds T, Lillis A, Maitland K, Foster G, Hadley J ( 2012 ) . MORTALITY AND UTILITY OF PROGNOSTIC SCORING MODELS IN CIRRHOTIC PATIENTS ADMITTED TO A TERTIARY NON-TRANSPLANT INTENSIVE CARE UNIT (ICU) IN THE UK . JOURNAL OF HEPATOLOGY . vol. 56 , S251 - S251 .

Pianko S, Zeuzem S, Chuang W-L, Foster GR, Sarin SK, Flisiak R, Lee C-M, Andreone P et al. ( 2012 ) . Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3 . JOURNAL OF VIRAL HEPATITIS vol. 19 , ( 9 ) 623 - 634 .

Jacobson IM, Jensen DM, Pol S, Foster GR, Feld JJ, Yoshida EM, Jablkowski MS, Perez-Gomez HR et al. ( 2012 ) . Safety and efficacy of ritonavir-boosted danoprevir (DNVr), peginterferon α-2a (40KD) (P) and ribavirin (R) with or without mericitabine in HCV genotype (G)1-infected treatment-experienced patients with advanced hepatic fibrosis . HEPATOLOGY . vol. 56 , 232A - 233A .

Alazawi W, Waters JA, Heath H, Woodfin A, O'Brien A, Jacobs M, Goldin R, Nourshargh S et al. ( 2012 ) . Stat2 loss is associated with enhanced inflammatory cell egress and hepatitis after LPS stimulation despite abolishing inflammatory cytokine production: a novel model of liver inflammation . HEPATOLOGY . vol. 56 , 1098A - 1099A .

Readhead S, Ahmed A, Jenkins H, Nicholls M, Berry P, Foster G, Ala A ( 2012 ) . THE USE OF DRY BLOOD SPOT TESTING (DBS) FOR VIRAL HEPATITIS IN MOSQUES-A PILOT STUDY OF 3 SURREY CENTRES . GUT vol. 61 , A131 - A131 .

Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hezode C, Hirschfield G et al. ( 2012 ) . TMC435 IN HCV GENOTYPE 1 PATIENTS WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: FINAL SVR24 RESULTS OF THE ASPIRE TRIAL . JOURNAL OF HEPATOLOGY . vol. 56 , S1 - S2 .

Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski J-P et al. ( 2012 ) . The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C . HEPATOLOGY vol. 55 , ( 3 ) 749 - 758 .

Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC et al. ( 2012 ) . UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients . ALIMENTARY PHARMACOLOGY & THERAPEUTICS vol. 35 , ( 6 ) 647 - 662 .

Feld JJ, Jacobson IM, Jensen DM, Foster GR, Pol S, Tam E, Berak H, Vierling JM et al. ( 2012 ) . Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine (MCB) and ribavirin (R) ± peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study . HEPATOLOGY . vol. 56 , 231A - 232A .

Thompson AJ, Patel K, Chuang W-L, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, Flisiak R, Pianko S et al. ( 2012 ) . Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3 . GUT vol. 61 , ( 1 ) 128 - 134 .

Lewis H, Burke K, Begum S, Ushiro-Limb I, Foster G ( 2012 ) . WHAT IS THE BEST METHOD OF CASE FINDING FOR CHRONIC VIRAL HEPATITIS IN AT-RISK MIGRANT COMMUNITIES? . JOURNAL OF HEPATOLOGY . vol. 56 , S351 - S351 .

Lewis H, Ibrahim N, Mirza M, Hothi J, Wilkinson M, Foster GR ( 2011 ) . ACTIVELY INJECTING DRUG USERS CAN BE SUCCESSFULLY TREATED WITH ANTIVIRAL THERAPY FOR HCV, ARE UNLIKELY TO BE RE-INFECTED, AND SIGNIFICANTLY REDUCE THEIR ILLICIT DRUG USE . HEPATOLOGY . vol. 54 , 846A - 847A .

Foster GR, Coppola C, Derbala MF, Ferenci P, Orlandini A, Tallarico LG, Ahlers S, Tatsch F et al. ( 2011 ) . BASELINE PREDICTORS FOR SAFETY-RELATED DOSE REDUCTIONS OR TREATMENT DISCONTINUATIONS AMONG PATIENTS (PTS) TREATED WITH PEGINTERFERON ALFA-2A (40KD) (PEGIFN alpha) PLUS RIBAVIRIN (RBV) AND THEIR IMPACT ON EARLY TREATMENT RESPONSES: INTERIM ANALYSIS FROM GUARD-C . HEPATOLOGY . vol. 54 , 837A - 837A .

Gill U, Al-Shamma S, Burke KB, Ross VA, Marley R, Kooner P, Foster GR, Kennedy PT ( 2011 ) . BONE MINERAL DENSITY LOSS IN TENOFOVIR TREATED CHRONIC HEPATITIS B VIRUS (HBV) PATIENTS IS A CONSEQUENCE OF VITAMIN D DEFICIENCY AND NOT TENOFOVIR THERAPY . HEPATOLOGY . vol. 54 , 1012A - 1012A .

Zeuzem S, Foster GR, Andreone P, Pol S, Lawitz E, Diago M, Roberts SK, Pockros P et al. ( 2011 ) . DIFFERENT LIKELIHOOD OF ACHIEVING SVR ON A TELAPREVIR-CONTAINING REGIMEN AMONG NULL RESPONDERS, PARTIAL RESPONDERS AND RELAPSERS IRRESPECTIVE OF SIMILAR RESPONSES AFTER A PEGINTERFERON/RIBAVIRIN 4-WEEK LEAD-IN PHASE: REALIZE STUDY SUBANALYSIS . HEPATOLOGY . vol. 54 , 986A - 987A .

Pol S, Roberts SK, Andreone P, Younossi ZM, Diago M, Lawitz E, Focaccia R, Foster GR et al. ( 2011 ) . EFFICACY AND SAFETY OF TELAPREVIR-BASED REGIMENS IN CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1 AND PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE: SUBANALYSIS OF THE REALIZE PHASE III STUDY . HEPATOLOGY . vol. 54 , 374A - 375A .

Kennedy PT, Sandalova E, Jo J, Gill U, Li L, Ushiro-Lumb I, Naik S, Foster GR et al. ( 2011 ) . IMMUNOLOGICAL ANALYSIS AND CLINICAL PROFILE OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION IN THE YOUNGER PATIENT . HEPATOLOGY . vol. 54 , 1092A - 1093A .

Roberts SK, Andreone P, Pol S, Younossi ZM, Diago M, Lawitz E, Focaccia R, Foster GR et al. ( 2011 ) . IMPACT OF ANEMIA AND RIBAVIRIN DOSE REDUCTION ON SVR TO A TELAPREVIR-BASED REGIMEN IN PATIENTS WITH HCV GENOTYPE 1 AND PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE IN THE PHASE III REALIZE STUDY . HEPATOLOGY . vol. 54 , 1007A - 1008A .

Younossi ZM, Negro F, Serfaty L, Pol S, Diago M, Zeuzem S, Andreone P, Lawitz E et al. ( 2011 ) . IMPACT OF INSULIN RESISTANCE ON VIROLOGIC RESPONSE TO A TELAPREVIR-BASED REGIMEN IN PATIENTS WITH HCV GENOTYPE 1 AND PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE: POST-HOC ANALYSIS OF THE REALIZE PHASE III STUDY . HEPATOLOGY . vol. 54 , 1008A - 1009A .

Pawlotsky JM, Flisiak R, Rasenack J, Sarin SK, Piratvisuth T, Chuang WL, Foster GR, Wedemeyer H et al. ( 2011 ) . ONCE DAILY ALISPORIVIR INTERFERON (IFN)-FREE REGIMENS ACHIEVE HIGH RATES OF EARLY HCV CLEARANCE IN PREVIOUSLY UNTREATED PATIENTS WITH HCV GENOTYPE (G) 2 OR 3 . HEPATOLOGY . vol. 54 , 1433A - 1433A .

Berg T, Andreone P, Pol S, Roberts SK, Younossi ZM, Diago M, Lawitz E, Focaccia R et al. ( 2011 ) . PREDICTORS OF VIROLOGIC RESPONSE WITH TELAPREVIR-BASED COMBINATION TREATMENT IN HCV GENOTYPE 1-INFECTED PATIENTS WITH PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE: POST-HOC ANALYSIS OF THE PHASE III REALIZE STUDY . HEPATOLOGY . vol. 54 , 375A - 376A .

Foster G, Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R et al. ( 2011 ) . OP03 Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results . Gut vol. 60 , ( Suppl 2 )

Foster GR, Pol S, Aerssens J, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, Younossi Z et al. ( 2011 ) . OP12 Similar Svr Rates In Il28b Cc, Ct Or Tt prior relapser, partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the Realize Study . Gut vol. 60 , ( Suppl 2 )

Lewis H, Ibrahim N, Mirza M, Hothi J, Wilkinson M, Foster G ( 2011 ) . P21 Actively injecting drug users can be successfully treated with antiviral therapy for HCV, are unlikely to be re-infected, and significantly reduce their illicit drug use . Gut vol. 60 , ( Suppl 2 )

Martin NK, Vickerman P, Foster GR, Miners A, Hutchinson SJ, Goldberg DJ, Hickman M ( 2011 ) . P53 The cost-effectiveness of HCV antiviral treatment for injecting drug user populations . Gut vol. 60 , ( Suppl 2 )

Waters J, Shoeb D, Foster GR ( 2011 ) . P55 HCV quasispecies analysis of patients with genotype 3 HCV who relapse suggest two different mechanisms of relapse . Gut vol. 60 , ( Suppl 2 )

Lewis H, Burke K, Begum S, Ushiro-Limb I, Foster G ( 2011 ) . P56 What is the best method of case finding for chronic viral hepatitis in migrant communities? . Gut vol. 60 , ( Suppl 2 )

Foster G ( 2011 ) . P59 Subanalyses of the Telaprevir lead-in arm in the realize study: response at week 4 is not a substitute for prior null response categorisation . Gut vol. 60 , ( Suppl 2 )

Gill US, Al-shamma S, Burke K, Ross V, Marley RTC, Kooner P, Foster GR, Kennedy PTF ( 2011 ) . P61 Bone mineral density loss in tenofovir treated Chronic Hepatitis B Virus (HBV) patients is a consequence of Vitamin D deficiency and not Tenofovir therapy . Gut vol. 60 , ( Suppl 2 )

Kennedy PTF, Sandalova E, Jo J, Gill US, Li L, Ushiro-Lumb I, Naik S, Foster GR et al. ( 2011 ) . P62 Immunological analysis and clinical profile of Chronic Hepatitis B Virus (HBV) infection in the younger patient . Gut vol. 60 , ( Suppl 2 )

Alazawi W, Gamero A, Heath H, Smith P, Jacobs M, Waters J, Foster GR ( 2011 ) . P93 NFκB activation by TLR agonists is deficient in macrophages lacking STAT2 . Gut vol. 60 , ( Suppl 2 )

Stamataki Z, Qureshi OS, Reynolds GM, Hibbert L, Waters J, Foster GR, Rappoport JZ, Hubscher SG et al. ( 2011 ) . P97 Lymphocyte-hepatocyte interactions: hepatitis C virus changes the rules . Gut vol. 60 , ( Suppl 2 )

Shoeb D, Rowe IA, Freshwater D, Mutimer D, Brown A, Moreea S, Sood R, Marley R et al. ( 2011 ) . Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse . Eur J Gastroenterol Hepatol vol. 23 , ( 9 ) 747 - 753 .

Foster GR, Hézode C, Bronowicki J-P, Carosi G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B et al. ( 2011 ) . Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections . Gastroenterology vol. 141 , ( 3 ) 881 - 889.e1 .

Shah SR, Patel K, Marcellin P, Foster GR, Manns M, Kottilil S, Healey L, Pulkstenis E et al. ( 2011 ) . Steatosis Is an Independent Predictor of Relapse Following Rapid Virologic Response in Patients With HCV Genotype 3 . CLIN GASTROENTEROL H vol. 9 , ( 8 ) 688 - 693 .

Patel K, Thompson AJ, Chuang WL, Lee CM, Peng CY, Shanmuganathan G, Thongsawat S, Tanwandee T et al. ( 2011 ) . Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients . J GASTROEN HEPATOL vol. 26 , ( 7 ) 1182 - 1188 .

Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M ( 2011 ) . Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility . J HEPATOL vol. 54 , ( 6 ) 1137 - 1144 .

Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z et al. ( 2011 ) . Telaprevir for retreatment of HCV infection . New England Journal of Medicine vol. 364 , ( 25 ) 2417 - 2428 .

Patel C, Gill US, Glyn F, Naik S, Foster GR, Kennedy PTF ( 2011 ) . CHRONIC HBV INFECTION: ASSESSMENT AND MANAGEMENT OF DISEASE IN A YOUNG ADULT CLINIC . GUT . vol. 60 ,

Glyn F, Gill US, Alazawi W, Ross V, Kooner P, Marley R, Foster GR, Kennedy PTF ( 2011 ) . EFFICACY OF COMBINATION TENOFOVIR PLUS LAMIVUDINE VERSUS TENOFOVIR MONOTHERAPY IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS . GUT . vol. 60 , A231 - A231 .

Gill US, Al-Shamma S, Burke K, Ross V, Marley R, Kooner P, Foster GR, Kennedy PTF ( 2011 ) . FACTORS DETERMINING BONE MINERAL DENSITY LOSS IN CHRONIC HEPATITIS B PATIENTS: IS TENOFOVIR DISOPROXIL FUMARATE THE MAIN CULPRIT? . GUT . vol. 60 ,

Gill U, Micco L, Li L, Peppa D, Ushiro-Lumb I, Foster GR, Maini MK, Kennedy PTF ( 2011 ) . PEGYLATED INTERFERON A MODULATES INNATE IMMUNITY IN EAG POSITIVE CHRONIC HEPATITIS B AND DETERMINES CHANGES IN HBSAG QUANTIFICATION . GUT . vol. 60 , A232 - A232 .

Cowan ML, Thomas HC, Foster GR ( 2011 ) . Therapy for chronic viral hepatitis: current indications, optimal therapies and delivery of care . CLIN MED vol. 11 , ( 2 ) 184 - 189 .

Gunawan A, Gill US, Glyn F, Kooner P, Marley R, Ushiro-Lumb I, Foster GR, Kennedy PTF ( 2011 ) . UTILITY OF HBSAG QUANTIFICATION IN DEVELOPING AN INDIVIDUALISED APPROACH TO THE MANAGEMENT OF CHRONIC HEPATITIS B VIRUS IN CLINICAL PRACTICE . GUT . vol. 60 ,

Lawitz E, Jacobson I, Godofsky E, Foster GR, Flisiak R, Bennett M, Ryan M, Hinkle J et al. ( 2011 ) . A PHASE 2B TRIAL COMPARING 24 TO 48 WEEKS TREATMENT WITH TEGOBUVIR (GS-9190)/PEG/RBV TO 48 WEEKS TREATMENT WITH PEG/RBV FOR CHRONIC GENOTYPE 1 HCV INFECTION . JOURNAL OF HEPATOLOGY . vol. 54 , S181 - S181 .

Gill US, Al-Shamma S, Burke K, Ross V, Kooner P, Marley R, Foster GR, Kennedy PTF ( 2011 ) . FACTORS DETERMINING BONE MINERAL DENSITY LOSS IN CHRONIC HEPATITIS B PATIENTS: IS TENOFOVIR DISOPROXIL FUMARATE THE MAIN CULPRIT? . JOURNAL OF HEPATOLOGY . vol. 54 , S286 - S286 .

Foster GR, Buggisch P, Marcellin P, Zeuzem S, Agarwal K, Manns M, Sereni D, Klinker H et al. ( 2011 ) . FOUR-WEEK TREATMENT WITH GS-9256 AND TEGOBUVIR (GS-9190), ± RBV ± PEG, RESULTS IN ENHANCED VIRAL SUPPRESSION ON FOLLOW-UP PEG/RBV THERAPY, IN GENOTYPE 1A/1B HCV PATIENTS . JOURNAL OF HEPATOLOGY . vol. 54 , S172 - S172 .

Stamataki Z, Qureshi OS, Reynolds GM, Mee C, Maurel P, Hibbert L, Waters JA, Foster GR et al. ( 2011 ) . LYMPHOCYTE-HEPATOCYTE INTERACTIONS: HEPATITIS C VIRUS CHANGES THE RULES . JOURNAL OF HEPATOLOGY . vol. 54 , S545 - S545 .

Stamataki Z, Qureshi OS, Reynolds GM, Hibbert L, Waters J, Foster GR, Rappoport JZ, Hubscher SG et al. ( 2011 ) . Lymphocyte interactions with hepatocytes: distinct mechanisms for T and B cells . IMMUNOLOGY . vol. 135 , 132 - 132 .

ALAZAWI W, Lewis H, Foster GR ( 2011 ) . Other Liver Viruses . Medicine vol. 39 , ( 9 ) 561 - 563 .

Gill US, Micco L, Li L, Peppa D, Ushiro-Lumb I, Foster GR, Maini MK, Kennedy PTF ( 2011 ) . PEGYLATED INTERFERON ALPHA MODULATES INNATE IMMUNITY IN EAG POSITIVE CHRONIC HEPATITIS B AND DETERMINES CHANGES IN HBSAG QUANTIFICATION . JOURNAL OF HEPATOLOGY . vol. 54 , S32 - S32 .

Zeuzem S, Andreone P, Pol S, Lawitz EJ, Diago M, Roberts S, Focaccia R, Younossi ZM et al. ( 2011 ) . REALIZE TRIAL FINAL RESULTS: TELAPREVIR-BASED REGIMEN FOR GENOTYPE 1 HEPATITIS C VIRUS INFECTION IN PATIENTS WITH PRIOR NULL RESPONSE, PARTIAL RESPONSE OR RELAPSE TO PEGINTERFERON/RIBAVIRIN . JOURNAL OF HEPATOLOGY . vol. 54 , S3 - S3 .

Foster G, Flisiak R, Chuang W-L, George J, Rasenack J, Sood A, Komolmit P, Thongsawat S et al. ( 2011 ) . RESPIRATORY ALTERATIONS IN GENOTYPE 2/3 CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGYLATED INTERFERON OR ALBINTERFERON-ALFA-2B PLUS RIBAVIRIN IN A RANDOMIZED STUDY . JOURNAL OF HEPATOLOGY . vol. 54 , S171 - S172 .

Pol S, Aerssens J, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, Younossi Z, Foster GR et al. ( 2011 ) . SIMILAR SVR RATES IN IL28B CC, CT OR TT PRIOR RELAPSER, PARTIAL- OR NULL-RESPONDER PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN: RETROSPECTIVE ANALYSIS OF THE REALIZE STUDY . JOURNAL OF HEPATOLOGY . vol. 54 , S6 - S7 .

Foster GR, Zeuzem S, Andreone P, Pol S, Lawitz EJ, Diago M, Roberts S, Pockros PJ et al. ( 2011 ) . SUBANALYSES OF THE TELAPREVIR LEAD-IN ARM IN THE REALIZE STUDY: RESPONSE AT WEEK 4 IS NOT A SUBSTITUTE FOR PRIOR NULL RESPONSE CATEGORIZATION . JOURNAL OF HEPATOLOGY . vol. 54 , S3 - S4 .

Mullhaupt B, Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R et al. ( 2011 ) . Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results . SWISS MEDICAL WEEKLY . vol. 141 , 6S - 6S .

Di Marco V, Capra M, Angelucci E, Borgna-Pignatti C, Telfer P, Harmatz P, Kattamis A, Prossamariti L et al. ( 2010 ) . Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel . BLOOD vol. 116 , ( 16 ) 2875 - 2883 .

Javaid A, Hibbert L, Waters JA, Alazawi W, Foster GR ( 2010 ) . CAN AN EX VIVO HUMAN LIVER BIOPSY MODEL BE USED TO TEST THE EFFICACY OF DRUGS FOR THE TREATMENT OF HEPATITIS C? . HEPATOLOGY . vol. 52 , 1217A - 1217A .

Martin NK, Vickerman P, Foster GR, Hutchinson S, Goldberg DJ, Hickman M ( 2010 ) . CAN ANTIVIRAL THERAPY FOR HEPATITIS C REDUCE THE PREVALENCE OF HCV AMONG INJECTING DRUG USER POPULATIONS? A MODELING ANALYSIS OF ITS PREVENTION UTILITY . HEPATOLOGY . vol. 52 , 808A - 809A .

Zeuzem S, Buggisch P, Agarwal K, Manns MP, Marcellins P, Foster GR, Sereni D, Klinker H et al. ( 2010 ) . DUAL, TRIPLE, AND QUADRUPLE COMBINATION TREATMENT WITH A PROTEASE INHIBITOR (GS-9256) AND A POLYMERASE INHIBITOR (GS-9190) ALONE AND IN COMBINATION WITH RIBAVIRIN (RBV) OR PEGIFN/RBV FOR UP TO 28 DAYS IN TREATMENT NAiVE, GENOTYPE 1 HCV SUBJECTS . HEPATOLOGY . vol. 52 , 400A - 401A .

Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J, Rosenberg WM ( 2010 ) . INDIVIDUALIZED CONCENTRATION MONITORED HIGH DOSE RIBAVIRIN IN COMBINATION WITH PEGINTERFERON TO HEPATITIS C GENOTYPE 1 PATIENTS WITH PREVIOUS NONRESPONSE . HEPATOLOGY . vol. 52 , 710A - 711A .

Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J, Rosenberg WM ( 2010 ) . PACIFIC: A PHASE III, RANDOMIZED, MULTICENTER, DOSE ESCALATION, EFFICACY AND SAFETY STUDY EXAMINING THE EFFECTS OF TREATMENT WITH PEGINTERFERON ALFA-2A IN PATIENTS WITH CHILD'S A OR B CIRRHOSIS IN CHRONIC HEPATITIS C VIRUS INFECTION . HEPATOLOGY . vol. 52 , 710A - 710A .

Foster GR, Shiffman ML, Hadziyanis SJ, Diago M, Nelson DR, Reddy R, Messinger D, Tatsch F ( 2010 ) . SAFETY AND VIROLOGIC RESPONSE RATES IN PATIENTS WITH HISTORY OF INJECTION DRUG USE (IDU): POOLED ANALYSIS OF DATA FROM FOUR RANDOMIZED PHASE III STUDIES OF PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN (RBV) . HEPATOLOGY . vol. 52 , 804A - 804A .

Foster GF, Dusheiko G, Hezode C, Marcellin P, McHutchison J, Beumont M, Kauffman B ( 2010 ) . OP11 Final results from telaprevir phase II studies in genotype 1 treatment-naive or experienced subjects with chronic hepatitis C . Gut vol. 59 , ( Suppl 2 )

Ahmed F, Foster GR ( 2010 ) . Global hepatitis, migration and its impact on Western healthcare . GUT vol. 59 , ( 8 ) 1009 - 1011 .

Alazawi W, Cunningham M, Dearden J, Foster GR ( 2010 ) . Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection . Aliment Pharmacol Ther vol. 32 , ( 3 ) 344 - 355 .

Byrne EAL, Katbamna R, Scott C, Blanshard C, Marley R, Coppack SW, Foster GR ( 2010 ) . Patients with m2 antibodies: what diagnosis and follow-up are they given? . Gut vol. 59 , ( 6 )

ALAZAWI W, Foster GR ( 2010 ) . Combination Therapy for Chronic Hepatitis B Virus Infection: Should we use it ab initio or Sequentially? . Clinical Dilemmas in Viral Liver Disease , Editors: Foster, G, Reddy, KR , Wiley-Blackwell

Uddin G, Shoeb D, Solaiman S, Marley R, Gore C, Ramsay M, Harris R, Ushiro-Lumb I et al. ( 2010 ) . Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin . J Viral Hepat vol. 17 , ( 5 ) 327 - 335 .

Alazawi W, Cunningham M, Dearden J, Foster GR ( 2010 ) . NATURAL HISTORY OF COMPENSATED CIRRHOSIS DUE TO CHRONIC HEPATITIS C INFECTION: A SYSTEMATIC REVIEW . GUT . vol. 59 , A101 - A101 .

Shoeb D, Rowe I, Brown A, Marley R, Freshwater D, Moreea S, Mutimer D, Foster G ( 2010 ) . RESPONSE TO ANTIVIRAL THERAPY IN GENOTYPE 3 HEPATITIS C-CIRRHOSIS AND DIABETES BUT NOT ETHNICITY REDUCE RESPONSE RATES . GUT . vol. 59 , A76 - A77 .

Foster GR, Reddy KR ( 2010 ) . Clinical Dilemmas in Viral Liver Disease .

Foster GR ( 2010 ) . HBeAg‐Negative Chronic Hepatitis B Infection with Abnormal Transaminases and Minimal Changes on Liver Biopsy . Clinical Dilemmas in Viral Liver Disease , Wiley

Foster GR ( 2010 ) . Hepatitis B Infection in Surgeons and Healthcare Workers: What should we do to Protect Patients? . Clinical Dilemmas in Viral Liver Disease , Wiley

Foster GR, Masson S ( 2010 ) . Most Patients with Hepatitis C will Die from their Disease . Clinical Dilemmas in Viral Liver Disease , Wiley

Foster GR ( 2010 ) . Novel Interferons: Is there Life in the Old Dog Yet? . Clinical Dilemmas in Viral Liver Disease , Wiley

Foster GR, Hezode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, Van Baelen B et al. ( 2010 ) . ACTIVITY OF TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 2 AND 3 HEPATITIS-C PATIENTS: FINAL RESULTS OF STUDY C209 . JOURNAL OF HEPATOLOGY . vol. 52 , S27 - S27 .

Gane E, Foster GR, Cianciara J, Stedman C, Ryder S, Buti M, Clark E, Tait D ( 2010 ) . ANTIVIRAL ACTIVITY, PHARMACOKINETICS, AND TOLERABILITY OF AZD7295, A NOVEL NS5A INHIBITOR, IN A PLACEBO-CONTROLLED MULTIPLE ASCENDING DOSE STUDY IN HCV GENOTYPE 1 AND 3 PATIENTS . JOURNAL OF HEPATOLOGY . vol. 52 , S464 - S464 .

De Meyer S, Ghys A, Foster GR, Beumont-Mauviel M, Van Baelen B, Lin TI, Dierynck I, Picchio G ( 2010 ) . Analyses of genotype 2/3 HCV variants in patients treated with telaprevir in study C209 showed that the telaprevir resistance profile appears to be consistent across genotypes . ANTIVIRAL THERAPY . vol. 15 , A118 - A118 .

De Meyer S, Foster GR, Ghys A, Beumont M, Van Baelen B, Lin TI, Picchio G ( 2010 ) . GENOTYPIC AND PHENOTYPIC CHARACTERIZATION OF GENOTYPE 2/3 HCV VARIANTS IN PATIENTS TREATED WITH TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A/RIBAVIRIN IN STUDY C209 . JOURNAL OF HEPATOLOGY . vol. 52 , S106 - S106 .

Alazawi W, Cunningham M, Dearden J, Foster GR ( 2010 ) . NATURAL HISTORY OF COMPENSATED CIRRHOSIS DUE TO CHRONIC HEPATITIS C INFECTION: A SYSTEMATIC REVIEW . JOURNAL OF HEPATOLOGY . vol. 52 , S402 - S402 .

Foster GR ( 2010 ) . Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b . Drugs vol. 70 , ( 2 ) 147 - 165 .

Thompson A, Diago M, Foster G, Ferenci P, Lurie Y, Stanciu C, Jablkowski M, Haussinger D et al. ( 2010 ) . RELATION BETWEEN SUSTAINED VIROLOGIC RESPONSE AND INSULIN RESISTANCE IN PATIENTS WITH GENOTYPE 1 OR 2/3 CHRONIC HEPATITIS C . JOURNAL OF HEPATOLOGY . vol. 52 , S25 - S25 .

Foster GR ( 2009 ) . Recent advances in viral hepatitis . CLIN MED vol. 9 , ( 6 ) 613 - 616 .

Barakat FM, McDonald V, Foster GR, Tovey MG, Korbel DS ( 2009 ) . Cryptosporidium parvum infection rapidly induces a protective innate immune response involving type I interferon . J Infect Dis vol. 200 , ( 10 ) 1548 - 1555 .

Al-Mahtab M, Rahman S, Karim F, Foster G, Solaiman S ( 2009 ) . Epidemiology of Hepatitis C Virus in Bangladeshi General Population . Bangabandhu Sheikh Mujib Medical University Journal vol. 2 , ( 1 ) 14 - 17 .

Alazawi W, Cottle R, Ross V, Ushiro-Lumb I, Alstead EM, Glynn M, Marley R, Foster GR ( 2009 ) . SUBSTITUTION OF ADEFOVIR FOR TENOFOVIR IN PATIENTS WITH CHRONIC HBV RECEIVING COMBINATION THERAPY WHO HAVE INCOMPLETE CONTROL OR VIROLOGICAL BREAKTHROUGH - IS IT WORTH-WHILE? . HEPATOLOGY . vol. 50 , 501A - 501A .

Foster GR ( 2009 ) . Quality of life considerations for patients with chronic hepatitis C . J Viral Hepat vol. 16 , ( 9 ) 605 - 611 .

Foster GR ( 2009 ) . Risks and benefits of treating chronic hepatitis C virus infection in injecting drug users .

Byrne EAL, Katbamna R, Scott C, Coppack SW, Foster GR ( 2009 ) . PATIENTS WITH M2 ANTIBODIES-WHAT DIAGNOSIS AND FOLLOW-UP ARE THEY GIVEN? . GUT . vol. 58 , A68 - A68 .

Foster GR, Hezode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, Vangeneugden T et al. ( 2009 ) . ACTIVITY OF TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 2 AND 3 HEPATITIS-C PATIENTS: INTERIM RESULTS OF STUDY C209 . JOURNAL OF HEPATOLOGY . vol. 50 , S22 - S22 .

Wilkinson M, Crawford V, Tippet A, Jolly F, Turton J, Sims E, Hekker M, Dalton J et al. ( 2009 ) . Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use . Aliment Pharmacol Ther vol. 29 , ( 1 ) 29 - 37 .

Alazawi W, Gamero A, Waters J, Jacobs M, Foster G ( 2009 ) . STAT2 IS A MAJOR DETERMINANT OF HEPATIC INFLAMMATION AND MORTALITY IN A KNOCKOUT MOUSE MODEL OF PERITONEAL INFLAMMATION . JOURNAL OF HEPATOLOGY . vol. 50 , S307 - S307 .

Hibbert L, Almazrouee S, Brown A, Barnes E, Foster GR ( 2009 ) . UPREGULATION OF REGULATORY T CELLS AND REDUCTION OF ANTI-VIRAL IMMUNE RESPONSES TO HEPATITIS C DURING VIRAL ERADICATION IN PATIENTS UNDERGOING ANTIVIRAL TREATMENT . JOURNAL OF HEPATOLOGY . vol. 50 , S320 - S320 .

Booth JCL, Foster GR, Levine T, Thomas HC, Goldin RD ( 2008 ) . The relationship of histology to genotype in chronic HCV infection . Liver International vol. 17 , ( 3 ) 144 - 151 .

Mahtab MA, Rahman S, Karim MF, Khan M, Foster G, Solaiman S, Afroz S ( 2008 ) . Epidemiology of hepatitis B virus in Bangladeshi general population . HEPATOB PANCREAT DIS vol. 7 , ( 6 ) 595 - 600 .

Alazawi W, Foster GR ( 2008 ) . Advances in the diagnosis and treatment of hepatitis B . Curr Opin Infect Dis vol. 21 , ( 5 ) 508 - 515 .

Uddin G, Faster GR ( 2008 ) . TITLE: PREVALENCE OF CHRONIC VIRAL HEPATITIS IN SOUTH ASIANS IMMIGRANTS - PEOPLE FROM PAKISTAN HAVE HIGH RATES OF INFECTION WITH HEPATITIS C AND HIGH RATES OF HEPATITIS C INDUCED CIRRHOSIS IN MIDDLE AGE . HEPATOLOGY . vol. 48 , 533A - 533A .

Foster GR ( 2008 ) . Injecting drug users with chronic hepatitis C: should they be offered antiviral therapy? . Addiction vol. 103 , ( 9 ) 1412 - 1413 .

de Ruiter A, Mercey D, Anderson J, Chakraborty R, Clayden P, Foster G, Gilling-Smith C, Hawkins D et al. ( 2008 ) . British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008 . HIV MED vol. 9 , ( 7 ) 452 - 502 .

COOK HT, EBRAHIM H, JANSEN AS, FOSTER GR, LARGEN P, CATTELL V ( 2008 ) . Expression of the gene for inducible nitric oxide synthase in experimental glomerulonephritis in the rat . Clinical & Experimental Immunology vol. 97 , ( 2 ) 315 - 320 .

Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M ( 2008 ) . Erratum: The way forward in HCV treatment — finding the right path . Nature Reviews Drug Discovery vol. 7 , ( 5 ) 458 - 458 .

Foster G ( 2008 ) . Interferons in Host Defense . Seminars in Liver Disease vol. 17 , ( 04 ) 287 - 295 .

Foster G, Carman W, Thomas H ( 2008 ) . Replication of Hepatitis B and Delta Viruses: Appearance of Viral Mutants . Seminars in Liver Disease vol. 11 , ( 02 ) 121 - 127 .

Foster G, Mathurin P ( 2008 ) . Hepatitis C virus therapy to date . Antivir Ther vol. 13 Suppl 1 , 3 - 8 .

Dakin HA, Foster GR, James ES ( 2008 ) . Results of a mixed treatment comparison meta-analysis of nucleoside and nucleotide therapies for HBeAG-positive chronic hepatitis B . JOURNAL OF HEPATOLOGY . vol. 48 , S256 - S256 .

Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M ( 2008 ) . The way forward in HCV treatment - finding the right path (vol 6, pg 991, 2007) . NAT REV DRUG DISCOV vol. 7 , ( 1 ) 83 - 83 .

Foster G, Karayiannis P, Lok A, Thomas H ( 2007 ) . Editorial . Journal of Viral Hepatitis vol. 15 , ( 1 ) 1 - 1 .

Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR ( 2007 ) . Interferons at age 50: past, current and future impact on biomedicine . Nat Rev Drug Discov vol. 6 , ( 12 ) 975 - 990 .

Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M ( 2007 ) . The way forward in HCV treatment - finding the right path . NAT REV DRUG DISCOV vol. 6 , ( 12 ) 991 - 1000 .

Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M ( 2007 ) . The way forward in HCV treatment--finding the right path . Nat Rev Drug Discov vol. 6 , ( 12 ) 991 - 1000 .

Foster GR, Nkhoma ANS ( 2007 ) . Hepatitis B and C Viruses — How do They Affect Management of IBD? . Clinical Dilemmas in Inflammatory Bowel Disease , Wiley

Coyle FM, Taylor NF, Monson JP, Drake WM, Foster GR ( 2007 ) . Non-alcoholic fatty liver disease is associated with transcriptional dysregulation of the corticosteroid metabolising enzyme II beta HSD-1 leading to excess intrahepatic steroid exposure . HEPATOLOGY . vol. 46 , 741A - 741A .

Foster GR, Karayiannis P, Lok A, Thomas HC ( 2007 ) . Editorial . J VIRAL HEPATITIS vol. 14 , ( 9 ) 599 - 599 .

Brideau-Andersen AD, Huang X, Sun S-CC, Chen TT, Stark D, Sas IJ, Zadik L, Dawes GN et al. ( 2007 ) . Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseases . Proc Natl Acad Sci U S A vol. 104 , ( 20 ) 8269 - 8274 .

Avraamides G, Ng C-Y, David R, Gu Y, Fazekasova H, Mirenda V, Foster GR, Runkel L et al. ( 2007 ) . IFN-alpha2 induces leukocyte integrin redistribution, increased adhesion, and migration . J Interferon Cytokine Res vol. 27 , ( 4 ) 291 - 303 .

Mitchell P, Germain C, Fiori PL, Khamri W, Foster GR, Ghosh S, Lechler RI, Bamford KB et al. ( 2007 ) . Chronic exposure to Helicobacter pylori impairs dendritic cell function and inhibits Th1 development . Infect Immun vol. 75 , ( 2 ) 810 - 819 .

Foster GR, Fried MW, Hadziyannis SJ, Messinger D, Freivogel K, Weiland O ( 2007 ) . Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin . Scand J Gastroenterol vol. 42 , ( 2 ) 247 - 255 .

Hibbert L, Foster GR ( 2007 ) . Effects of telapravir (VX950) in a liver biopsy model of HCV infection: Genotype 1 virions are inhibited in vitro but other genotypes are less responsive . JOURNAL OF HEPATOLOGY . vol. 46 , S227 - S227 .

Bentley I ( 2007 ) . Improving practice . Drugs in Context vol. 4 , 1 - 7 .

Hibbert L, Foster GR ( 2007 ) . Interferon induced gene induction and the anti-viral effects of ifn alpha in liver biopsies with hepatitis C: Viral and host responses determine treatment efficacy . JOURNAL OF HEPATOLOGY . vol. 46 , S226 - S227 .

Thomas T, Foster G ( 2007 ) . Nanomedicines in the treatment of chronic hepatitis C - focus on pegylated interferon alpha-2a . INT J NANOMED vol. 2 , ( 1 ) 19 - 24 .

Wilkinson M, Sims E, Tippett A, Hekker M, Dalton J, Turton J, Jolly F, Crawford V et al. ( 2007 ) . Therapy for chronic hepatitis C in active injectors: A nurse led clinic allows effective therapy and leads to a reduction in illicit drug use . JOURNAL OF HEPATOLOGY . vol. 46 , S204 - S205 .

Thomas H, Foster G, Karayiannis P ( 2006 ) . Editorial . Journal of Viral Hepatitis vol. 14 , ( 1 ) 1 - 1 .

Barton A, Choudhury A, Shanmugasundaram P, McAvinia P, Coyle F, Foster G, Kuitert L ( 2006 ) . Association between abnormal hepatic enzymes, fatty change in the liver, and acute pulmonary infection in cystic fibrosis . THORAX . vol. 61 , II121 - II122 .

Szmaragd C, Foster GR, Manica A, Bartholomeusz A, Nichols RA, Balloux F ( 2006 ) . Genome-wide characterisation of Hepatitis B mutations involved in clinical outcome . HEREDITY vol. 97 , ( 6 ) 389 - 397 .

Platis D, Foster GR ( 2006 ) . Interferon Proteins: Structure, Production and Purification . The Interferons , Wiley

Hollander A, Foster GR, Weiland O ( 2006 ) . Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C . Scand J Gastroenterol vol. 41 , ( 5 ) 577 - 585 .

Jones M, Strang AL, Hibbert L, Smith PL, Jacobs MG, Foster GR ( 2006 ) . HCVNS5A protein - Functional analysis using a BVDV replicon reporter system shows a correlation between in vitro effects on interferon sensitivity and clinical outcome . JOURNAL OF HEPATOLOGY . vol. 44 , S153 - S154 .

Szmaragd C, Foster GR, Manica A, Bartholomeusz A, Nichols RA, Balloux F ( 2006 ) . Hepatitis B virus mutations involved in clinical outcome . JOURNAL OF HEPATOLOGY . vol. 44 , S151 - S151 .

Swain MG, Foster GR, Hadziyannis SJ, Heathcote EJ, Jensen D, Lee SS, Pockros PJ, Sulkowski M et al. ( 2006 ) . Poor prognostic factors in heavier patients with chronic hepatitis C (CHC) result in less favourable treatment outcomes . JOURNAL OF HEPATOLOGY . vol. 44 , S227 - S227 .

Foster GR, Karayiannis P, Thomas HC ( 2006 ) . Untitled . J VIRAL HEPATITIS vol. 13 , ( 1 ) 1 - 1 .

Foster GR, Goldin RD, Hay A, McGarvey MJ, Stark GR, Thomas HC ( 2005 ) . Expression of the terminal protein of hepatitis B virus is associated with failure to respond to interferon therapy . Hepatology vol. 17 , ( 5 ) 757 - 762 .

Tamir A, Jordan WJ, Ritter M, Habib N, Lechler RI, Foster GR, Lombardi G ( 2005 ) . Interferon-alpha2a is sufficient for promoting dendritic cell immunogenicity . Clin Exp Immunol vol. 142 , ( 3 ) 471 - 480 .

Swain MG, Foster G, Hadziyannis S, Heathcote J, Jensen D, Lee S, Pockros P, Sulkowski M et al. ( 2005 ) . Clustering of poor prognostic factors in heavier patients with chronic hepatitis C (CHC): Baseline characteristics and outcomes with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus ribavirin (RBV, COPEGUS (R)) in randomized, international, Phase III trials . HEPATOLOGY . vol. 42 , 687A - 688A .

Scott K, Manunta M, Germain C, Smith P, Jones M, Mitchell P, Dessi D, Bamford KB et al. ( 2005 ) . Qualitatively distinct patterns of cytokines are released by human dendritic cells in response to different pathogens . IMMUNOLOGY vol. 116 , ( 2 ) 245 - 254 .

D'Souza R, Glynn MJ, Ushiro-Lumb I, Feakins R, Domizio P, Mears L, Alsced E, Kumar P et al. ( 2005 ) . Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhood . Clin Gastroenterol Hepatol vol. 3 , ( 9 ) 910 - 917 .

Hawkins D, Blott M, Clayden P, De Ruiter A, Foster G, Gilling‐Smith C, Gosrani B, Lyall H et al. ( 2005 ) . Guidelines for the management of HIV infection in pregnant women and the prevention of mother‐to‐child transmission of HIV . HIV Medicine vol. 6 , ( S2 ) 107 - 148 .

D'Souza R, Sabin CA, Foster GR ( 2005 ) . Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy . Am J Gastroenterol vol. 100 , ( 7 ) 1509 - 1515 .

Jones M, Davidson A, Hibbert L, Gruenwald P, Schlaak J, Ball S, Foster GR, Jacobs M ( 2005 ) . Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression . J VIROL vol. 79 , ( 9 ) 5414 - 5420 .

Foster GR, Suddle AR ( 2005 ) . Treatment of HCV infection with pegylated interferons . Current Hepatology Reports vol. 4 , ( 2 ) 49 - 55 .

Smith PL, Lombardi G, Foster GR ( 2005 ) . Type I interferons and the innate immune response--more than just antiviral cytokines . Mol Immunol vol. 42 , ( 8 ) 869 - 877 .

Foster GR ( 2005 ) . Apoptotic cell death: the caspase-cleavage "gold rush" . Lancet vol. 365 , ( 9467 ) 1293 - 1294 .

D'Souza R, Sinnott P, Glynn MJ, Sabin CA, Foster GR ( 2005 ) . An unusual form of autoimmune hepatitis in young Somalian men . Liver Int vol. 25 , ( 2 ) 325 - 330 .

Swain M, Foster GR, Fried MW, Hadziyannis SJ, Heathcote EJ, Jensen D, Lee SS, Pockros PJ et al. ( 2005 ) . Clustering of poor prognostic factors in patients with chronic hepatitis C . JOURNAL OF HEPATOLOGY . vol. 42 , 222 - 222 .

Weiland O, Fried MW, Hadziyannis S, Messinger D, Freivogel K, Foster GR ( 2005 ) . Peginterferon alpha-2a (40 kDa) plus ribavirin in treatment-naive patients with chronic hepatitis C and genotype 2 or 3 infection: Individual estimated probability of sustained virological response . JOURNAL OF HEPATOLOGY . vol. 42 , 226 - 227 .

D'Souza RFC, Feakins R, Mears L, Sabin CA, Foster GR ( 2005 ) . Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C . Aliment Pharmacol Ther vol. 21 , ( 5 ) 519 - 524 .

D'Souza R, Main J, Crossey M, Rosenberg W, Murray-Lyon IM, Hayward C, Foster GR ( 2005 ) . Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy -- patients' views of early cessation of therapy . Aliment Pharmacol Ther vol. 21 , ( 1 ) 43 - 47 .

Lim AKP, Taylor-Robinson SD, Patel N, Eckersley RJ, Goldin RD, Hamilton G, Foster GR, Thomas HC et al. ( 2005 ) . Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C . Gut vol. 54 , ( 1 ) 128 - 133 .

FOSTER GR, Feakins R, Kumar P, Alstead E, D'Souza R, Glynn MJ, Mears L, Sabin CA et al. ( 2005 ) . Natural History of Chronic Hepatitis C Infection: Long Term Follow-up of Asian Patients Infected in Childhood . Clin Gastroenterol Hepatol vol. 3 , 910 - 917 .

Foster GR ( 2004 ) . Novel interferons . ANTIVIRAL THERAPY . vol. 9 , H4 - H4 .

D'Souza R, Foster G ( 2004 ) . Pegylated interferons . Journal of Drug Evaluation vol. 2 , ( 4 ) 113 - 127 .

Caronia S, McGarvey MJ, Goldin RD, Foster GR ( 2004 ) . Negative correlation between intrahepatic expression of hepatitis C antigens and apoptosis despite high-level expression of Fas and HLA antigens . J Viral Hepat vol. 11 , ( 6 ) 511 - 518 .

Foster GR ( 2004 ) . Review article: pegylated interferons: chemical and clinical differences . Aliment Pharmacol Ther vol. 20 , ( 8 ) 825 - 830 .

Jones M, Germain C, Lechler RI, Lombardi G, Foster GR ( 2004 ) . Immunomodulatory properties of the type I interferons: Type I interferons can both activate and inhibit Th1 activation . HEPATOLOGY . vol. 40 , 345A - 345A .

Suddle A, Foster G, Powell-Tuck J ( 2004 ) . The nutritional and metabolic management of hepatic failure in european liver units - a surprising lack of consensus? . CLIN NUTR vol. 23 , ( 5 ) 953 - 954 .

Pollara G, Jones M, Handley ME, Rajpopat M, Kwan A, Coffin RS, Foster G, Chain B et al. ( 2004 ) . Herpes simplex virus type-1-induced activation of myeloid dendritic cells: the roles of virus cell interaction and paracrine type IIFN secretion . J IMMUNOL vol. 173 , ( 6 ) 4108 - 4119 .

Foster G ( 2004 ) . Best treatment for chronic HCV in 2004 . JOURNAL OF VIRAL HEPATITIS . vol. 11 , 36 - 36 .

D'Souza RFC, Glynn MJ, Alstead E, Foster GR, Ushiro-Lumb I ( 2004 ) . Improving hepatitis C services across the UK: response to a walk-in HCV testing service . Gut vol. 53 , ( 9 )

Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, Cheinquer H, Craxi A et al. ( 2004 ) . Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C . Am J Gastroenterol vol. 99 , ( 8 ) 1490 - 1496 .

Foster GR, Masri SH, David R, Jones M, Datta A, Lombardi G, Runkell L, de Dios C et al. ( 2004 ) . IFN-alpha subtypes differentially affect human T cell motility . J Immunol vol. 173 , ( 3 ) 1663 - 1670 .

Foster GR, Masri SH, David R, Jones M, Datta A, Lombardi G, Runkell L, De Dios C et al. ( 2004 ) . IFN-α subtypes differentially affect human T cell motility . Journal of Immunology vol. 173 , ( 3 ) 1663 - 1670 .

D'Souza RFC, Glynn MJ, Alstead E, Foster GR, Osonayo C ( 2004 ) . Improving general practitioners' knowledge of chronic hepatitis C infection . QJM vol. 97 , ( 8 ) 549 - 550 .

D'Souza R, Foster GR ( 2004 ) . Diagnosis and Treatment of Chronic Hepatitis B . Journal of the Royal Society of Medicine vol. 97 , ( 7 ) 318 - 321 .

D'Souza R, Foster GR ( 2004 ) . Diagnosis and treatment of chronic hepatitis B . J R Soc Med vol. 97 , ( 7 ) 318 - 321 .

D'Souza RFC, Glynn MJ, Alstead E, Osonayo C, Foster GR ( 2004 ) . Knowledge of chronic hepatitis C among East London primary care physicians following the Department of Health's educational campaign . QJM vol. 97 , ( 6 ) 331 - 336 .

Reed JR, Vukmanovic-Stejic M, Fletcher JM, Soares MVD, Cook JE, Orteu CH, Jackson SE, Birch KE et al. ( 2004 ) . Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivo . J Exp Med vol. 199 , ( 10 ) 1433 - 1443 .

D'Souza R, Foster GR ( 2004 ) . Diagnosis and treatment of hepatitis C . J R Soc Med vol. 97 , ( 5 ) 223 - 225 .

Weiland O, Fried MW, Hadziyannis SJ, Foster GR, Messinger D, Freivogel K, Chaneac M ( 2004 ) . Combination therapy with peginterferon alfa-2a (40kd) (PEGASYS (R)) plus ribavirin (COPEGUS (R)) in treatment-naive patients with chronic hepatitis C and genotype 1 infection: Individual estimated probability of sustained virological response (SVR) . JOURNAL OF HEPATOLOGY . vol. 40 , 154 - 154 .

D'Souza RFC, Glynn MJ, Alstead E, Osonoya C, Foster GR ( 2004 ) . Knowledge of chronic hepatitis C among East London primary care physicians following the Department of Health's educational campaign . JOURNAL OF HEPATOLOGY . vol. 40 , 139 - 140 .

D'Souza R, Alstead E, Glynn M, Kumar P, Sabin C, Ushiro-Lumb I, Mears L, Feakins R et al. ( 2004 ) . Natural history of chronic hepatitis C infection: Long term follow up of Asian patients infected in childhood . GUT . vol. 53 , A81 - A82 .

Nkhoma ANS, Macey M, Foster GR ( 2004 ) . Transition from acute to chronic viral infections - A tissue culture model using respiratory syncitial virus infected cells . GUT . vol. 53 , A82 - A82 .

Mangia A, Leandro G, Helbling B, Renner EL, Tabone M, Sidoli L, Caronia S, Foster GR et al. ( 2004 ) . Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials . J Hepatol vol. 40 , ( 3 ) 478 - 483 .

Thomas H, Foster G, Platis D ( 2004 ) . Mechanisms of action of interferon and nucleoside analogues (vol 39, pg S93, 2003) . J HEPATOL vol. 40 , ( 2 ) 364 - 364 .

Thomas HC, Foster GR, Karayiannis P ( 2004 ) . Editorial . Journal of Viral Hepatitis vol. 11 , ( 1 ) 1 - 1 .

Foster GR, Goldin RD ( 2004 ) . Management of chronic viral hepatitis, second edition .

Foster GR ( 2004 ) . Past, present, and future hepatitis C treatments . Semin Liver Dis vol. 24 Suppl 2 , 97 - 104 .

Foster GR, Goldin RD, Thomas HC ( 2003 ) . Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis . Hepatology vol. 27 , ( 1 ) 209 - 212 .

Thomas HC, Török ME, Foster GR ( 2003 ) . Hepatitis C virus dynamics in vivo and the antiviral efficacy of interferon alfa therapy . Hepatology vol. 29 , ( 4 ) 1333 - 1334 .

Platis D, Foster GR ( 2003 ) . Activity of hybrid type I interferons in cells lacking Tyk2: a common region of IFN-alpha 8 induces a response, but IFN-alpha2/8 hybrids can behave like IFN-beta . J Interferon Cytokine Res vol. 23 , ( 11 ) 655 - 666 .

GOLDIN RD, LEVINE TS, FOSTER GR, THOMAS HC ( 2003 ) . GRANULOMAS AND HEPATITIS C . Histopathology vol. 28 , ( 3 ) 265 - 267 .

Foster GR, D'Souza RFC, Main J, Crossey M, Rosenberg W, Murray-Lyon IM, Hayward C ( 2003 ) . Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy - Is it worthwhile? . HEPATOLOGY . vol. 38 , 646A - 646A .

Platis D, Foster GR ( 2003 ) . High yield expression, refolding, and characterization of recombinant interferon alpha2/alpha8 hybrids in Escherichia coli . Protein Expr Purif vol. 31 , ( 2 ) 222 - 230 .

D'Souza R, Foster GR ( 2003 ) . Transmission of hepatitis C: An overview . International Journal of Medicine vol. 5 , ( 4 ) 232 - 234 .

Foster GR, Fried MW, Hadziyannis SJ, Chaneac M ( 2003 ) . Treatment of chronic hepatitis C with peginterferon alfa-2a (40KD) (PEGASYS (R)) and ribavirin (COPEGUS (R)): Patient age has a marked influence on the individual estimated probability of achieving a sustained virological response . HEPATOLOGY . vol. 38 , 246A - 246A .

Judd A, Parry J, Hickman M, McDonald T, Jordan L, Lewis K, Contreras M, Dusheiko G et al. ( 2003 ) . Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots . J MED VIROL vol. 71 , ( 1 ) 49 - 55 .

Foster GR ( 2003 ) . Hepatitis C: an Australian perspective . DRUG-EDUC PREV POLIC vol. 10 , ( 2 ) 206 - 207 .

Shonde T, Collier J, Lorton A, Lyon IM, Freedman A, Wiselka M, Jack K, Hayward C et al. ( 2003 ) . Interim results from a multi-centre clinical trial of interferon with ribavirin compared to interferon with ribavirin and amantadine in previously untreated patients with chronic hepatitis C . GUT . vol. 52 ,

Foster GR ( 2003 ) . Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus . Expert Opin Pharmacother vol. 4 , ( 5 ) 685 - 691 .

Waters JA, Jones M, Jacobs M, Roberts P, Karayiannis P, Thomas HC, Foster GR ( 2003 ) . Effects of interferon on HCV and EMCV replication in the same cell line: Interferon inhibitory NS5A sequences do not inhibit the effects of IFN when expressed in the replicon . JOURNAL OF HEPATOLOGY . vol. 38 , 9 - 9 .

Dick EA, Joarder R, de Jode M, Taylor-Robinson SD, Thomas HC, Foster GR, Gedroyc WMW ( 2003 ) . MR-guided laser thermal ablation of primary and secondary liver tumours . Clin Radiol vol. 58 , ( 2 ) 112 - 120 .

Foster GR, Tudor-Williams G, White J, Regan L ( 2003 ) . Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus . BJOG vol. 110 , ( 1 )

Thomas H, Foster G, Platis D ( 2003 ) . Mechanisms of action of interferon and nucleoside analogues . J Hepatol . vol. 39 Suppl 1 , S93 - S98 .

Mangia A, Leandro G, Helbling B, Renner EL, Tabone M, Sidoli L, Caronia S, Foster GR et al. ( 2002 ) . Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: Meta-analysis of individual patient data from 6 clinical trials . HEPATOLOGY . vol. 36 , 570A - 570A .

Jensen CDM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, Cheinquer H, Craxi A, Cooksley WGE et al. ( 2002 ) . Modeling the impact of peginterferon alfa-2a (40KD) (Pegasys (R)) plus ribavirin therapy on life expectancy and medical care costs in chronic hepatitis C . HEPATOLOGY . vol. 36 , 603A - 603A .

Sebire NJ, Goldin RD, Main J, Foster G ( 2002 ) . Placental histopathology in maternal hepatitis C virus infection: a morphological and immunohistochemical study . J PATHOL vol. 198 , 22A - 22A .

( 2002 ) . The Journal of Viral Hepatitis goes electronic . Journal of Viral Hepatitis vol. 9 , ( 2 ) 81 - 81 .

Lim AKP, Patel N, Hamilton G, Blomley MJK, Cosgrove DO, Foster GR, Goldin RD, Thomas HC et al. ( 2002 ) . A prospective assessment of hepatic vein transit times using microbubble-enhanced ultrasound in non-invasive grading of hepatitis C (HCV) related liver disease . GUT vol. 50 , A53 - A53 .

Platis D, Germain C, Lombardi G, Foster G ( 2002 ) . Immunomodulatory properties of pegylated interferons: The 40 kD pegylated IFN alfa 2a has greater Th1 stimulatory activity than the 12 kD pegylated IFN alfa 2b . J HEPATOL vol. 36 , 124 - 124 .

Lim A, Patel N, Hamilton G, Blomley M, Cosgrove D, Foster G, Goldin R, Thomas H et al. ( 2002 ) . Non-invasive grading of hepatitis C related liver disease: Microbubble-enhanced ultrasound studies . J HEPATOL vol. 36 , 116 - 116 .

Foster GR ( 2002 ) . Management of chronic hepatitis C--time for a change? . J Viral Hepat vol. 9 , ( 2 ) 82 - 83 .

Foster GR, Finter NB ( 2002 ) . Are all Type I human interferons equivalent? . Journal of Viral Hepatitis vol. 5 , ( 3 ) 143 - 152 .

Schulte-Frohlinde E, Seidler B, Burkard I, Freilinger T, Lersch C, Erfle V, Foster GR, Classen M ( 2002 ) . Different activities of type I interferons on hepatitis B virus core promoter regulated transcription . Cytokine vol. 17 , ( 4 ) 214 - 220 .

Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, Wesnes KA, Taylor-Robinson SD ( 2002 ) . Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease . Hepatology vol. 35 , ( 2 ) 433 - 439 .

FOSTER GR ( 2002 ) . The clinical effectiveness of pegylated interferons in the management of chronic hepatitis C . Aids and Hepatitis Digest vol. 89 , 3 - 5 .

Caronia S, Bassendine MF, Barry R, Mills P, Naoumov NV, Fox R, Lowes J, Hollanders D et al. ( 2001 ) . Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study . J Hepatol vol. 35 , ( 4 ) 512 - 516 .

Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD ( 2001 ) . Evidence for a cerebral effect of the hepatitis C virus . Lancet vol. 358 , ( 9275 ) 38 - 39 .

Paterson M, Laxton C, Goldin RD, Ackrill AM, Foster GR ( 2001 ) . Selection of HCV NS5A quasispecies during IFN therapy in patients with chronic HCV . Dig Dis Sci vol. 46 , ( 7 ) 1399 - 1408 .

Forton D, Murphy C, Allsop J, Main J, Foster GR, Thomas HC, Taylor-Robinson SD ( 2001 ) . Correlation between neuropsychometric scores and cerebral proton magnetic resonance spectroscopy (1H-MRS) in chronic hepatitis C infection . J HEPATOL vol. 34 , 160 - 160 .

Leyland M, Torok ME, Acheson J, Foster GR ( 2000 ) . Hepatitis C virus infection is not associated with a marked increase in the prevalence of ophthalmic morbidity . EYE vol. 14 , 889 - 891 .

Foster GR, Germain C, Jones M, Lechler RI, Lombardi G ( 2000 ) . Human T cells elicit IFN‐α secretion from dendritic cells following cell to cell interactions . European Journal of Immunology vol. 30 , ( 11 ) 3228 - 3235 .

Crofts N, Caruana S, Bowden S, Kerger M ( 2000 ) . Minimising harm from hepatitis C virus needs better strategies . The BMJ vol. 321 , ( 7265 )

Caronia S, Gulati V, McGarvey MJ, Goldin RD, Foster GR ( 2000 ) . Hepatitis C virus infected hepatocytes and apoptosis . HEPATOLOGY vol. 32 , ( 4 ) 265A - 265A .

Ward C, Tudor-Williams G, Cotzias T, Hargreaves S, Regan L, Foster GR ( 2000 ) . Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: uptake and acceptability of named antenatal testing . Gut vol. 47 , ( 2 )

( 2000 ) . Preface . Best Practice & Research Clinical Gastroenterology vol. 14 , ( 2 )

Foster GR, Thomas HC ( 2000 ) . Therapeutic options for HCV—management of the infected individual . Best Practice & Research Clinical Gastroenterology vol. 14 , ( 2 ) 255 - 264 .

Foster GR, Thomas HC ( 2000 ) . Journal of Viral Hepatitis: Editorial . Journal of Viral Hepatitis vol. 7 , ( 1 )

Paterson M, Laxton CD, Thomas HC, Ackrill AM, Foster GR ( 1999 ) . Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response . Gastroenterology vol. 117 , ( 5 ) 1187 - 1197 .

Foster GR, Scott DA, Payne S ( 1999 ) . The use of CT scanning in dementia. A systematic review . International Journal of Technology Assessment in Health Care vol. 15 , ( 2 ) 406 - 423 .

Hibbert L, Foster GR ( 1999 ) . Human Type I Interferons Differ Greatly in Their Effects on the Proliferation of Primary B Cells . Journal of Interferon & Cytokine Research vol. 19 , ( 4 ) 309 - 318 .

Foster GR ( 1999 ) . Hepatitis C virus infection: quality of life and side effects of treatment . Journal of Hepatology . vol. 31 , 250 - 254 .

Foster GR, Thomas HC ( 1999 ) . Journal of Viral Hepatitis: Editorial . Journal of Viral Hepatitis vol. 6 , ( 1 )

Foster GR ( 1998 ) . Amantadine in the treatment of patients with chronic hepatitis C . Digestive and Liver Disease vol. 30 , ( 6 ) 614 - 615 .

Schulte-Frohlinde E, Foster GR ( 1998 ) . Spontaneous Seroconversion in Chronic Hepatitis B: Role of Mutations in the Precore/Core Gene . Digestive Diseases and Sciences vol. 43 , ( 8 ) 1714 - 1718 .

Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC ( 1997 ) . Increase in primary liver cancer in the UK, 1979–94 . The Lancet vol. 350 , ( 9085 ) 1142 - 1143 .

Foster GR, Goldin RD, Main J, Murray-Lyon I, Hargreaves S, Thomas HC ( 1997 ) . Management of chronic hepatitis C: clinical audit of biopsy based management algorithm . The BMJ vol. 315 , ( 7106 )

Foster GR, Rodrigues O, Ghouze F, Schulte-Frohlinde E, Testa D, Liao MJ, Stark GR, Leadbeater L et al. ( 1996 ) . Different Relative Activities of Human Cell-Derived Interferon-α Subtypes: IFN-α8 Has Very High Antiviral Potency . Journal of Interferon & Cytokine Research vol. 16 , ( 12 ) 1027 - 1033 .

Thomas H, Foster G, Sumiya M, Mclntosh D, Jack D, Turner M, Summerfield J ( 1996 ) . Mutation of gene for mannose-binding protein associated with chronic hepatitis B viral infection . The Lancet vol. 348 , ( 9039 ) 1417 - 1419 .

Rani MRS, Foster GR, Leung S, Leaman D, Stark GR, Ransohoff RM ( 1996 ) . Characterization of β-R1, a Gene That Is Selectively Induced by Interferon β (IFN-β) Compared with IFN-α* . Journal of Biological Chemistry vol. 271 , ( 37 ) 22878 - 22884 .

Teare JP, Price DA, Foster GR, McBride M, Goldin RD, Main J ( 1995 ) . Reversible AIDS-related sclerosing cholangitis . Journal of Hepatology vol. 23 , ( 2 ) 209 - 211 .

Booth JC, Foster GR, Kumar U, Galassini R, Goldin RD, Brown JL, Thomas HC ( 1995 ) . Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon alpha . Gut vol. 36 , ( 3 )

Foster GR, Ackrill AM, Goldin RD, Kerr IM, Thomas HC, Stark GR ( 1995 ) . Erratum: Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons α and γ and double-stranded RNA (Proceedings of the National Academy of Sciences of the United States of America (April 1991) 88:7 (2888-2892)) . Proceedings of the National Academy of Sciences of the United States of America vol. 92 , ( 8 )

Thomas HC, Foster GR, Booth J ( 1995 ) . How to improve the results from interferon treatment of hepatitis C virus infection . Interferons and Cytokines ( 26 ) 13 - 16 .

Foster GR, Thomas HC ( 1994 ) . Effects of hepatitis B and hepatitis C virus replication on the actions of interferon . Antiviral Research vol. 24 , ( 2-3 ) 131 - 136 .

Craske J, Paver WK, Neeleman J, Unwin C, Farrel M, Foster GR, Thomas HC ( 1994 ) . Hepatitis C virus infection . The BMJ vol. 308 , ( 6945 )

Foster GR, Thomas HC ( 1994 ) . Hepatitis C virus infection. Treatment with interferon reduces viraemia . The BMJ vol. 308 , ( 6945 )

Block TM, Lu X, Platt FM, Foster GR, Gerlich WH, Blumberg BS, Dwek RA ( 1994 ) . Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin . Proceedings of the National Academy of Sciences of the United States of America vol. 91 , ( 6 ) 2235 - 2239 .

Foster GR, Thomas HC ( 1993 ) . Recent advances in the molecular biology of hepatitis B virus: mutant virus and the host response . Gut vol. 34 , ( 1 )

Cooper CM, Foster GR, Cooper AE, Kenny M, Olivera DB ( 1991 ) . Serum F-protein concentration following halothane or isoflurane anaesthesia . Clinica Chimica Acta vol. 202 , ( 1-2 ) 73 - 82 .

Yeo WW, Foster G, Ramsay LE ( 1991 ) . Prevalence of persistent cough during long-term enalapril treatment: controlled study versus nifedipine . QJM vol. 80 , ( 293 ) 763 - 770 .

Ackrill AM, Foster GR, Laxton CD, Flavell DM, Stark GR, Kerr IM ( 1991 ) . Inhibition of the cellular response to interferons by products of the adenovirus type 5 E1A oncogene . Nucleic Acids Research vol. 19 , ( 16 ) 4387 - 4393 .

Foster GR, Ackrill AM, Goldin RD, Kerr IM, Thomas HC, Stark GR ( 1991 ) . Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA . Proceedings of the National Academy of Sciences of the United States of America vol. 88 , ( 7 ) 2888 - 2892 .

Foster GR, Goldin RD, Freeth CJ, Nieman E, Oliveira DB ( 1991 ) . Liver damage in long-term anticonvulsant therapy: a serological and histological study . QJM vol. 79 , ( 288 ) 315 - 322 .

Foster GR, Ackrill AM, Golden RD, Goodbourn SE, Kerr IM, Thomas HC, Stark GR ( 1991 ) . Inhibitory effects of the hepatitis B virus on the cellular response to interferon . International Journal of Experimental Pathology . vol. 72 ,

Foster GR, Carmichael DJS, Kermode A, Hulme B, Gabriel JRT, Cattell V ( 1990 ) . Extensive Crescent Formation with Antifibrinolytic Therapy in a Case of Diffuse Endocapillary Glomerulonephritis . Nephrology Dialysis Transplantation vol. 5 , ( 2 ) 152 - 154 .

Beckett GJ, Foster GR, Hussey AJ, Oliveira DB, Donovan JW, Prescott LF, Proudfoot AT ( 1989 ) . Plasma glutathione S-transferase and F protein are more sensitive than alanine aminotransferase as markers of paracetamol (acetaminophen)-induced liver damage . Clinical Chemistry vol. 35 , ( 11 ) 2186 - 2189 .

Foster GR, Goldin RD, Oliveira DBG ( 1989 ) . Serum F protein: A new sensitive and specific test of hepatocellular damage . Clinica Chimica Acta vol. 184 , ( 1 ) 85 - 92 .

Foster GR ( 1988 ) . Behçet's Colitis with Oesophagael Ulceration Treated with Sulphasalazine and Cyclosporin . Journal of the Royal Society of Medicine vol. 81 , ( 9 ) 545 - 546 .

FOSTER GR, BOWNESS P, HOLDER K, OLIVEIRA DBG ( 1988 ) . HEPATOTOXICITY AFTER GENERAL ANAESTHESIA . British Journal of Anaesthesia vol. 61 , ( 1 ) 120 - 121 .